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Abstract
New sequencing and array technologies for transcriptome-wide profiling of RNAs
have greatly promoted the interest in gene and isoform-based functional characteriza-
tions of a cellular system. Many statistical and machine learning methods have been de-
veloped to quantify the isoform/gene expression and identify the transcript variants for
cancer outcome prediction. Since building reliable learning models for cancer transcrip-
tome analysis relies on accurate modeling of prior knowledge and interactions between
the cellular components, it is still a computational challenge.
This thesis proposes several robust and reliable learning models to integrate both
large-scale array and sequencing data with biological prior knowledge for cancer tran-
scriptome analysis. First, we explore two signed network propagation algorithms and
general optimization frameworks for detecting differential gene expressions and DNA
copy number variations (CNV). Second, we present a network-based Cox regression
model called Net-Cox and applied Net-Cox for a large-scale survival analysis across
multiple ovarian cancer datasets to identify highly consistent signature genes and im-
prove the accuracy of survival prediction. Third, we introduce a Network-based method
for RNA-Seq-based Transcript Quantification (Net-RSTQ) to integrate protein domain-
domain interaction network with short read alignments for transcript abundance esti-
mation. Finally, we perform computational analysis of mRNA 3’-UTR shortening on
mouse embryonic fibroblast (MEF) cell lines to understand changes of molecular features
on dysregulated activation of mammalian target of rapamycin (mTOR).
We evaluate our models and findings with simulations and real genomic datasets.
The results suggest that our models explore the global topological information in the
networks, improve the transcript quantification for better sample classification, iden-
tified consistent biomarkers to improve cancer prognosis and survival prediction. The
analysis of 3’-UTR with RNA-Seq data find an unexpected link between mTOR and
ubiquitin-mediated proteolysis pathway through 3’-UTR shortening.
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Chapter 1
Introduction
1.1 Background
Messenger RNA (mRNA) is a large family of RNA molecules. It carries codes from
the DNA and translated into proteins. Since mRNA expression is strongly correlated
with protein activities, it is often used as a signature in cancer analysis. Transcriptomic
technologies such as mRNA-Sequencing (RNA-Seq) and Microarrays have given us the
ability to analyze cellular mRNA levels globally, which enable effective molecular phe-
notyping of cancers, providing novel insights into the disease. Some pioneer works have
shown that the mRNA expression patterns caused by BRCA1 or BRCA2 mutation are
associated with either a poor prognosis or a good prognosis of breast cancer and ovarian
cancer [1–3] by analysing microarray gene expression data.
In the human transcriptome, there are ∼21,000 protein coding genes and many of
these genes can encode multiple protein isoforms. Besides transcript isoforms, there are
other transcript variants such as gene fusion and alterative polyadenylation can still
be introduced into mRNA and affect the expression of gene and isoforms. Moreover,
as a complex disease, cancer is believed to be caused by a combination of the effects
of multiple transcript variants. Therefore, analyzing cancer trascriptomes is still a
challenge. In this thesis, we focus on three specific problems in understanding cancer
trascriptome and list them below.
1
2Alternative splicing A single gene contains numerous exons and introns, the exons
can be spliced together in different ways. Recent studies have estimated that alternative
splicing events exist in 92-94% of multi-exon genes in human, resulting in more than
one transcript per gene [4]. An example of an alternative splicing event is illustrated
in Figure 1.1(A). The gene contains 5 exons, one of the mRNA transcribed from that
gene contains exons 1-4 and another contains exons 1-3, and exon 5, which produce
two protein isoforms from the same gene. Alternative splicing provides cells with the
opportunity to create protein isoforms of differing functions from a single gene. Can-
cer cells often take advantage of this flexibility that promote growth and survival [5].
Many isoforms produced in this way are developmentally regulated and preferentially
re-expressed in tumor [5,6]. Therefore, accurate transcript quantification is crucial and
enables us to detect the differences of the alternative transcripts in the gene under differ-
ent conditions. Its downstream application in detecting molecular signature for cancer
can greatly impact biomedical study.
Alternative polyadenylation The 3’ end of most protein-coding genes and non-
coding RNAs is polyadenylated. Recent studies using transcriptome-wide techniques
have revealed that most human or mouse genes contain more than one poly(A) site, in-
dicating alternative polyadenylation (ApA) [7]. Tandem 3’ untranslated region (UTR)
ApA, illustrated in Figure 1.1(B), involves the occurrence of alternative poly(A) sites
within the same terminal exon is one of the most frequent ApA forms. 3’-UTR ApA
generates multiple isoforms with different 3’-UTR length without affecting the protein
encoded by the gene. It potentially regulates the stability, cellular localization and
translation efficiency of target RNAs as 3’-UTR provides a binding platform for mi-
croRNAs and RNA-binding proteins. A recently recognized mechanism of oncogene
activation is the loss of microRNA complementary sites [8, 9]. Therefore, identifying
cancer relevant 3’-UTR shortening events can possibly improve disease prognosis and
diagnosis.
Interactions It is well known that gene, transcript or protein isoforms do not function
in isolation in the cell, but are integrated together as a network of interactions between
3Figure 1.1: (A) Alternative Splicing, (B)Tandem 3’-UTR Alternative
Polyadenylation, and (C) Protein-Protein interaction subnetworks.
cellular components. Two human protein-protein interaction (PPI) subnetworks ob-
tained from HPRD [10] are shown in Figure 1.1(C). Cancer, as a complex disease,
reflects the perturbations or breakdown of specific functional modules in the complex
cellular network, rather than a consequence of an abnormality in a single gene [11].
Thus, instead of considering the gene or transcript variant individually in the cancer
transcriptome analysis, integrating network and high-throughput information together
could probably improve the quality of the analysis [12]. However, due to the complex
4and heterogeneous nature of these large-scale datasets, efficient and reliable computa-
tional methods that integrate network information for cancer transcriptome analysis are
crucially needed.
1.2 Previous Methods
We will review a few fundamental modeling techniques that have been widely used in
cancer transcriptome analysis. Our models proposed in this thesis are developed based
on these base models. 1) Network propagation, a popular method for feature section by
integrating network information into analysis [13–15]; 2) Cox proportional hazard model
[16], widely used in survival analysis for biomarker identification and survival prediction;
3) A base Expectation-Maximization(EM) model [17, 18] for transcript quantification
with RNA-Seq data.
1.2.1 Network propagation
Let G = (V,W ) denote an undirected graph with vertex set V and positive adjacency
matrix W ∈ R+|V |×|V |. In network propagation, the vertex set V is initialized by a
vector y which is the +1/− 1 label on training vertices and 0 on test vertices in binary
classification. In the regularization framework proposed by [13], the objective is to learn
a label assignment function f : V → R to assign labels to the test vertices. The cost
function is defined as follows,
Ω(f) =
∑
i,j
Wij(
fi√
Dii
− fj√
Djj
)2 + %‖f − y‖2, (1.1)
where D is a diagonal matrix with Dii =
∑
jWij and % ≥ 0 is a parameter to weight the
two terms in the cost function. The first term in Eqn. (1.1) is the smoothness constraint,
which encourages assigning similar labels to strongly connected vertices. The second
term is the fitting constraint, which encourages consistency between predictions and
training labels. The first term can be rewritten as
f ′(I − (D)− 12W (D)− 12 )f,
where I − (D)− 12W (D)− 12 is the normalized graph Laplacian, which is positive semi-
definite. Thus Eqn. (1.1) is a quadratic problem with a closed-form solution.
5In transcriptome analysis, G denotes a gene correlation graph, each vertex represent
a gene, and the edge represent the relation between two genes. The initial labels, y,
provide the differential expression of each individual gene in the case/control study as
the starting point of propagation. After convergence, f gives a new ranking of the genes.
1.2.2 Cox proportional hazard model
Consider the Cox regression model proposed in [16]. Given X, the gene expression
profile of n patients over p genes, the instantaneous risk of an event at time t for the ith
patient with gene expressions Xi = (Xi1, ..., Xip)
′ is given by
h(t|Xi) = h0(t)exp(X ′iβ), (1.2)
where β = (β1, ..., βp)
′ is a vector of regression coefficients, and h0(t) is an unspecified
baseline hazard function. In the classical setting with n > p, the regression coefficients
are estimated by maximizing the Cox’s log-partial likelihood:
pl(β) =
n∑
i=1
δi
X ′iβ − log
 ∑
j∈R(ti)
exp(X ′jβ)
 , (1.3)
where ti is the observed or censored survival time for the i
th patient, and δi is an
indicator of whether the survival time is observed (δi = 1) or censored (δi = 0). R(ti) is
the risk set at time ti, i.e. the set of all patients who still survived prior to time ti. The
commonly used Breslow estimator [19] to estimate the baseline hazard h0(t) is given by
hˆ0(ti) = 1/
∑
j∈R(ti)
exp(X ′jβˆ). (1.4)
The partial likelihood and the Breslow estimator are induced by the total log-likelihood
l(β, h0) =
n∑
i=1
{−exp(X ′iβ)H0(ti) + δi [log(h0(ti)) +X ′iβ]}, (1.5)
with
H0(ti) =
∑
tk≤ti
h0(tk). (1.6)
The optimal regression coefficients β is estimated based on the maximization of the total
log-likelihood by alternating between maximization with respect to β (with Newton-
Raphson) and h0(t) (by equation (1.4)).
61.2.3 Base EM model for transcript quantification
Let Ti denote the set of the transcripts in the ith gene and Tik be the kth transcript
in Ti. The probability of a read being generated by the transcripts in Ti is modeled
by a categorical distribution specified by parameters pik, where
∑|Ti|
k=1 pik = 1 and
0 ≤ pik ≤ 1. For the set of the reads ri aligned to gene i, we consider the likelihood
of that each of the |ri| short reads is sampled from one of the transcripts to which the
read aligns. Specifically, for each read rij aligned to transcript Tik, the probability of
obtaining rij by sampling from Tik, namely Pr(rij |Tik) is qijk = 1lik−lr+1 [20–22], where
lr is the length of the read. Assuming each read is independently sampled from one
transcript, the uncommitted likelihood function [17] to estimate the parameters Pi from
the observed read alignments against gene i is
L(Pi; ri) = Pr(ri|Pi) =
|ri|∏
j=1
Pr(rij |Pi) =
|ri|∏
j=1
|Ti|∑
k=1
Pr(Tik|Pi)Pr(rij |Tik)
=
|ri|∏
j=1
|Ti|∑
k=1
pikqijk. (1.7)
This likelihood function is concave but it may contain plateau in the likelihood surface.
Therefore, Expectation Maximization (EM) is then applied to obtain the optimal Pi. In
the EM algorithm, the expectation of read assignments to transcripts were estimated in
the E-step and the likelihood function with the expected assignments can be maximized
in the M-step to estimate Pi. The relative abundance of the transcript Tik in gene i,
ρik, can be derived from
ρik =
pik
lik∑|Ti|
k=1
pik
lik
, (1.8)
and the transcript expressions in gene i, piik, can be calculated by
piik =
|ri|pik
lik
. (1.9)
The base model is applied independently to each individual gene and no relation among
the transcripts is considered.
71.3 Challenges and Objectives
As shown above, many statistical and machine learning methods have been developed to
quantify the transcript/gene expression [23,24], discover gene and transcript variants as
molecular signatures (biomarkers) [2,25], and predict survival in patients with potential
clinical value [26], but building reliable learning models for estimating the isoform ex-
pression and discovering consistent biomarkers for prediction of clinical outcomes using
high-throughput dataset is still a key challenge in transcriptome analysis.
• Many of the current approaches for biomarker discovery and survival prediction
are based on univariate statistical analysis such as the Cox regression model (equa-
tion (1.3)). There are two major limitations of these popular methods. First, the
genomic features are ranked by their individual correlation with the phenotype.
In complex diseases, such as cancer is believed to be caused by the interactions
of multiple genes as well as environmental factors, which can not be captured by
traditional univariate analysis. Though network propagation algorithms (equa-
tion (1.1)) can overcome this limitation, they only work on positively weighted
graphs. Second, usually all the samples are used to compute the correlation with
phenotype, and thus biomarkers specific to only a subset of the samples are not
detectable [27].
• In current isoform quantification methods for RNA-Seq data analysis, solely based
on short read alignment could be overly optimistic to derive the proportion of the
isoforms of a gene such as the base EM model (equation (1.7)). First, in the aligned
RNA-Seq short reads, most reads mapped to a gene are potentially originated by
more than one transcript [28]. The ambiguous mapping could result in hardly
identifiable patterns of transcript variants [29]. Second, various sampling biases
have been observed regularly in RNA-Seq data from library preparation, include
position-specific bias, start and end biases, and sequences-specific bias. How to
get accurate transcript quantification remains a challenging problem.
• Approximately 70% genes [30] are characterized by multiple polyA sites that pro-
duce distinct transcript isoforms with different 3’-UTR length and content, thereby
significantly contributing to transcriptome diversity [31]. However, methods to
8quantify relative ApA usage are still limited. Besides that, very few RNA-seq
reads contain polyA tails, challenging our ability to identify ApA events in gene.
For example, an ultra-deep sequencing study [32] only identified ∼40 thousand pu-
tative polyA reads (∼0.003%) from 1.2 billion total RNA-seq reads [33]. Moreover,
the precise mechanism(s) of ApA events is unknown [34].
1.4 Contributions
To address the challenges described above, we propose four different models and studies
in this thesis.
First, we introduce signed network propagation frameworks for detecting consistent
biomarkers [27]. The first framework runs network propagation on a gene graph weighted
by both positive and negative gene co-expression for gene selection from gene expression
datasets. It integrates gene co-expression and differential expression to explore gene
modules which overcome the limitation of the biomarker identification models based
on univariate statistical analysis. The second framework runs network propagation on
sample-feature bipartite graphs linked by both positive and negative features to identify
gene or CNV markers. The framework explores bi-clusters between patients and features
to find biomarkers specific to subsets of patient samples.
Second, we propose a network-based Cox proportional hazard model to explore the
co-expression or functional relation among gene expression features for survival anal-
ysis [35], which to our knowledge is among the first models that directly incorporate
network information in survival analysis. A gene relation network constructed by co-
expression analysis or prior knowledge of gene functional relations models the relation-
ship between genes. In the model, a graph Laplacian constraint is introduced as a
smoothness requirement on the gene features linked in the gene relation network. The
model identified consistent signature genes across the three ovarian cancer datasets, and
because of the better generalization across the datasets, the model also consistently im-
proved the accuracy of survival prediction over the Cox models regularized by L2-norm
or L1-norm.
Third, we examine the possibility of using protein domain-domain interactions as
9prior knowledge in isoform transcript quantification to overcome the limitation of sam-
pling bias from RNA-Seq data [36]. We first made the observation that protein domain-
domain interactions positively correlate with isoform co-expressions in TCGA data and
then designed a probabilistic EM approach to integrate domain-domain interactions with
short read alignments for estimation of isoform proportions. In simulation, the approach
effectively improved isoform transcript quantifications when isoform co-expressions cor-
relate with their interactions. qRT-PCR results on 25 multi-isoform genes in a stem cell
line, ovarian cancer cell line, and a breast cancer cell line also showed that the approach
estimated more consistent isoform proportions with RNA-Seq data. In the experiments
on the RNA-Seq data in TCGA, the transcript abundances estimated by the approach
are more informative for patient sample classification of ovarian cancer, breast cancer
and lung cancer.
Last, we developed a pipeline to identify the transcriptome-wide ApA events with
RNA-Seq data in mouse embryonic fibroblast (MEF) [34]. To detect the events, we
evaluated candidate polyA signal (PAS) motifs in the 3’-UTR of the transcript by con-
trasting the short-read coverage up/downstream of the site across wild-type (WT) and
TSC1−/− MEFs with χ2-test. To our knowledge, this is one of the first comprehen-
sive analysis of transcriptome-wide ApA events with RNA-Seq data. Besides that, in
this study we investigate the molecular signatures of mammalian target of rapamycin
(mTOR) activated transcriptome and discovered widespread 3’-UTR shortening due to
dysregulated mTOR activation. Moreover, we found almost all known 3’-end process-
ing factors alter their expression on changes in cellular mTOR activity in TSC1−/−
compared with WT MEF.
1.5 Data Repositories
In this thesis, we utilized public high-throughput genomic data from several sources. All
the processed RNA-Seq and microarray data were downloaded from The Cancer Genome
Atlas (TCGA) data portal and the Gene Expression Omnibus (GEO) repository. The
raw RNA-Seq fastq files were downloaded from Cancer Genomics Hub (CGHub) under
National Cancer Institute (NCI) and Sequence Read Archive (SRA) under National
Center for Biotechnology Information (NCBI).
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• TCGA project (http://cancergenome.nih.gov/) profiled and analyzed large
numbers of human tumors to discover molecular aberrations at the DNA, RNA,
protein and epigenetic levels. The resulting rich data provide a whole picture
to understand the molecular basis of cancer. TCGA data portal (https://
tcga-data.nci.nih.gov/tcga/dataAccessMatrix.htm) provides a platform for
researchers to search, download, and analyze data sets generated by TCGA. We
downloaded the normalized RNA-Seq and microarray gene expression and tran-
script expression data of four cancer types from the data portal.
• CGHub (https://cghub.ucsc.edu/) is the online repository of the sequencing
programs of the NCI, including The Cancer Genomics Atlas (TCGA) project [37].
The raw RNA-Seq fastq files of the cancer patients in four cancer types listed in
TCGA were downloaded from the CGHub online repository.
• GEO (http://www.ncbi.nlm.nih.gov/geo/) is a public repository that archives
and freely distributes microarray, next-generation sequencing, and other forms of
high-throughput functional genomic data submitted by the scientific community
[38]. We downloaded two ovarian cancer microarray gene expression datasets, five
breast cancer microarray gene expression datasets from the GEO repository.
• SRA (http://www.ncbi.nlm.nih.gov/sra) stores raw sequence data from next-
generation sequencing technologies. Two raw RNA-Seq fastq files of breast cancer
cell line and stem cell line were downloaded from the SRA database.
Besides above, our collaborators at University of Kansas Medical Center and University
of Minnesota also provided in-house data of ovarian cancer cell line and mouse cell line
for the studies.
1.6 Outline
The rest of the thesis is organized as follows:
• In Chapter 2, we describe two signed network propagation algorithms, Signed-NP
and Signed-NPBi, consider both positive and negative relation in graphs to model
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gene up/down-regulation or amplification/deletion CNV events for detecting dif-
ferential gene expressions and DNA CNVs.
• In Chapter 3, we describe a network-based Cox regression model called Net-Cox,
integrates gene network information into the Cox’s proportional hazard model
to explore the co-expression or functional relation among high-dimensional gene
expression features in the gene network for biomarker identification and survival
prediction.
• In Chapter 4, we describe a network-based probabilistic EM approach, Net-RSTQ,
to integrate domain-domain interations with short read alignments for estimation
of isoform proportions.
• In Chapter 5, we identifie 3’-UTR shortening of mRNAs as an additional molecular
signature of mTOR activation and show that 3’-UTR shortening enhances the
translation of specific mRNAs.
• In Chapter 6, we summarize the findings of the thesis and suggesting directions
for future work.
Chapter 2
Signed Network Propagation for
Cancer Biomarker Analysis
2.1 Introduction
Powered by high-throughput genomic technologies, it is now a common practice to per-
form genome-scale experiments for measuring gene expressions, copy number variations
(CNVs), single nucleotide polymorphisms, and other molecular information for cancer
studies. Correlating these high-dimensional genomic features with cancer phenotypes
as molecular signatures (biomarkers) can possibly improve prognosis and diagnosis over
current clinical measures for risk assessment of patients [2,39,40]. The most widely used
statistical methods to detect biomarkers are Pearson correlation coefficients [2] and hy-
pothesis test methods such as student t-test. There are two major limitations of these
popular methods. First, the genomic features are ranked by their individual correlation
with the phenotype, and thus relations among features, for example co-expressed genes
under certain conditions and adjacent probes involved in the same CNV events, are
ignored. Second, usually all the samples are used to compute the correlation with phe-
notype, and thus biomarkers specific to only a subset of the samples are not detectable.
Network propagation is a graph-based learning algorithm [13] similar to PageRank
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used by Google. It has been shown that network propagation is capable of captur-
ing the dependence among genomic features to detect correlated features as biomark-
ers [14, 15]. An efficient network propagation algorithm on bipartite graphs was in-
troduced to explore sample-feature bi-clusters for feature selection and cancer outcome
classification [41]. In the network propagation regularization framework, a quadratic
term with a normalized graph Laplacian matrix as hessian is combined with a square-
loss on the predictions to explore the global graph structure for capturing correlation
between all genomic features. The graph Laplacian matrix is only defined for positively
weighted graphs which poses a significant limitation on the applicability of network
propagation to the analysis of genomic data. For example, gene expression data could
require a precise representation of up-regulated expression or down-regulated expres-
sion, and CNV data require a precise representation of amplification or deletion events.
In these real computational biology problems, genomic data are represented by signed
graphs to incorporate both positive and negative relations and thus the existing network
propagation algorithms are not applicable.
To address the problem, we propose two signed network propagation algorithms
and regularization frameworks for detecting differential gene expressions and DNA copy
number variations. In the frameworks, we introduce signed graph Laplacians into net-
work propagation. The first algorithm, Signed-NP, runs network propagation on a gene
graph weighted by both positive and negative gene co-expressions for gene selection from
gene expression datasets. Signed-NP integrates gene co-expressions and differential ex-
pressions to explore gene modules. The second algorithm, Signed-NPBi, runs network
propagation on sample-feature bipartite graphs linked by both positive and negative
features to identify gene or CNV markers. Signed-NPBi explores bi-clusters between
patients and features to find biomarkers specific to subsets of patient samples.
2.2 Method
Based on the network propagation model described in section 1.2.1. We first introduce
signed network propagation (Signed-NP) in section 2.2.1 and its extension for propa-
gation on bipartite graphs (Signed-NPBi) in section 2.2.2. In section 2.2.3 and section
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2.2.4 we apply Signed-NP on gene correlation graphs for detecting differential gene ex-
pressions, and Signed-NPBi on sample-feature bipartite graphs for gene selection or
CNV detection respectively.
2.2.1 Signed Network Propagation
To allow both positive and negative edges for network propagation, we introduce signed
graph Laplacian [42] into the regularization framework. Given a signed graph G =
(V,W ) with vertices V and adjacency matrix W ∈ R|V |×|V |. The cost function of the
regularization framework is modified as follows,
Ω(f) =
∑
i,j
|Wij |( fi√
Dii
− sgn(Wij) fj√
Djj
)2 + %‖f − y‖2, (2.1)
where Dii =
∑
j |Wij |. The first term in Eqn.(2.1) is the normalized signed graph
Laplacian I − S, where S = D− 12 ∗ W ∗ D− 12 . It has been shown in [42] that the
signed graph Laplacian is always positive semi-definite. The first cost term encourages
assigning similar labels to vertices connected by positive edges and opposite labels to
the vertices connected by negative edges. Empirically, the eigenvalues of S can be very
small. For better performance in network propagation, we rescale S by dividing the
largest eigenvalue such that S’s eigenvalues are in the range [−1, 1]. Similar to the
algorithm proposed by [13], the optimization framework in Eqn.(2.1) can be solved with
an iterative label propagation algorithm,
f t = (1− α)y + αSf t−1, (2.2)
where t denotes the propagation step and α = 1/(1 +%). The parameter α balances the
weights between initial label and network structure. The larger the α, the more we trust
the network structure. This algorithm simply propagates labels among the neighbors
in the graph. The algorithm will converge to the closed-form solution
f∗ = (1− α)(I − αS)−1 ∗ y, (2.3)
where f∗ assigns labels to the vertices.
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2.2.2 Propagation on Signed Bipartite Graph
We next extend the framework in Eqn.(2.1) for signed bipartite graphs. Let G =
(V,U,E,W ) denote a signed bipartite graph, where V and U represent two disjoint
vertex sets, E is a set of weighted edges, and W ∈ RV×U is the wighted adjacency
matrix. Each edge (v, u) ∈ E connects two vertices v and u with weight Wvu. The
initialization function y for the two vertex sets are denoted by y(v) and y(u). In this
context, the cost function over G = (V,U,E,W ) is defined as
Ω(f) = 2
∑
(v,u)∈E
|Wvu|( f(v)√
Dvv
− sgn(Wvu) f(u)√
D′uu
)2
+%‖f(v)− y(v)‖2 + %‖f(u)− y(u)‖2, (2.4)
where % ≥ 0 is a parameter for balancing the cost terms, and D and D′ are diagonal
matrices with Dvv =
∑
u∈U |w(v, u)| and D′uu =
∑
v∈V |w(v, u)|. The first cost term
encourages similar labeling on positively connected vertex pairs and opposite labeling on
negatively connected pairs. The second term and the third term constrain the new label
assignment to be consistent with the initial labeling. To solve the optimization problem
in Eqn.(2.4), we can also use a similar network propagation algorithm to compute
the closed-form solution. The propagation algorithm iteratively performs propagation
between the two vertex sets in both directions as follow,
f(v)t = (1− α)y(v) + αSf(u)t−1
f(u)t = (1− α)y(u) + αSf(v)t−1
where α = 1/(1+%), S = D−
1
2 ∗W ∗D′− 12 , and t denotes the propagation step. S is also
similarly rescaled by dividing the largest eigenvalue. Label information is propagated
through neighbors in the bipartite graph. The algorithm will converge to the closed-form
solution as in Eqn.(2.3).
2.2.3 Learning with Gene Correlation Graph
We first apply Signed-NP to a gene correlation graph for identifying differentially ex-
pressed genes. An illustrative example of network propagation on a gene correlation
graph G = (V,W ) is shown in Figure 2.1. Each vertex in V represents a gene which
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Figure 2.1: Running Signed-NP on a gene correlation graph. A gene correla-
tion graph is constructed from gene expression data. The vertices are then initialized
by the correlation between each individual gene expression and the labels. Network
propagation on the signed graph re-rank all the genes for biomarker discovery.
is initialized by Pearson’s correlation coefficients between gene expressions and the
case/control labeling. An example of calculating the correlation between gene expres-
sion and labels is given in the pink rectangles in the figure. The initial labels provide the
differential expression of each individual gene in the case/control study as the starting
point of propagation. Each Wij is the Pearson’s correlation coefficients between gene
expressions of gene i and gene j. An example of computing the correlation between
gene expressions is given in the blue rectangles in the figure. Signed-NP propagates
the initial labels across the network and the propagation process assigns similar labels
to genes that are positively co-expressed and opposite labels to genes with opposite
expression. The intuition is that we assume marker genes are active either in the case
group or the control group but never both. Thus, the positive edges play the role to
join positively co-expressed genes and the negative edges play the role to distinguish the
genes with opposite expressions. After network propagation, the genes are re-ranked by
the magnitude from positive to negative. Figure 2.1 shows how label propagation can
capture the hidden clusters to recover false negatives and eliminate false positives. In
the example, we assume two hidden clusters in the network, one of which contains a
gene with initial value -0.23 and the another contains a gene with initial value 0.29 (the
two cyan nodes). After running label propagation, final scores are assigned by balancing
their coherence and discrimination so that genes in the same cluster are assigned similar
scores.
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2.2.4 Learning with Sample-Feature Bipartite Graph
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Figure 2.2: Running Signed-NPBi on sample-feature bipartite graph. Gene
expression data is modeled as a sample-feature bipartite graph. The sample vertices are
initialized by the case/control labels and the gene vertices are initialized with 0. Network
propagation classifies the unlabeled samples and ranks the genes by their importance.
We next apply Signed-NPBi to gene expression and CNV data for both genomic fea-
ture selection and sample classification. Gene expression data is modeled by a sample-
feature bipartite graph G = (V,U,E,W ) as illustrated in Figure 2.2, where V repre-
sents the set of sample vertices and U represents the set of gene vertices. Each edge
(v, u) ∈ E connects sample vertex v ∈ V and gene vertex u ∈ U weighted by Wvu as is
illustrated by the blue rectangles. The sample vertices in V are labeled with +1/-1/0
(case/control/unlabeled) as illustrated by the pink rectangle and the gene vertices are
initialized with zeros. In this modeling, Signed-NPBi explores those bi-cluster composed
of vertices with opposite labels and connected with negative edges as well as vertices
with similar labels and connected with positive edges. As explained in the signed graph
model in Eqn.(2.4), the first term in the cost function constrains new labeling to be
consistent between the positively connected sample-gene pairs and opposite between
the negatively connected sample-gene pairs. The second term is a fitting term which
keeps the new label assignment for each sample consistent with the initial label. For
the unlabeled vertices v ∈ V with y(v) = 0, the second term is used to regularize these
f(v)s such that the total cost is constrained. The third term is used in the same spirit
to constrain the cost on the gene vertices. The final scores obtained after convergence
are used to rank the genes as well as classify additional test (unlabeled) samples. In
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Figure 2.2 the optimal labels are given in parentheses. After running network propaga-
tion, the genes in bi-clusters will receive more significant values. Note that if connected
by negative edges, the sample and the gene will receive opposite labels. Since the im-
portant genes are strongly connected to either the case group or the control group we
can consider the genes with significant scores within the bi-clusters as biomarkers. The
unlabeled samples are also classified to different groups based on the sign of the final
score for each sample.
Similarly, we can also apply the signed bipartite graph model to copy number varia-
tion data. Each probe feature is represented by a vertex in U connected to the samples
with an edge weighted by the log intensity ratio of the probe. After network propaga-
tion, those probes with high scores are selected as important CNV regions. In CNV
analysis the adjacent probes tend to be strongly correlated, thus the bi-clusters in the
bipartite graph represent a continuous CNV regions across a subset of samples.
2.3 Experiments
In the experiments, we tested Signed-NP on 5 breast cancer gene expression datasets
to detect differentially expressed genes and Signed-NPBi on two breast cancer gene ex-
pression datasets and one bladder cancer arrayCGH dataset to detect both differentially
expressed genes and copy number variations.
2.3.1 Biomarker Identification from Gene Correlation Graph
GEO Index GSE1456 GSE2034 GSE3494 GSE6532 GSE7390
Study Pawitan Wang Miller Loi Desmedt
# of Meta 35 95 37 51 35
# of Meta-free 35 114 150 96 136
Table 2.1: Samples in five breast cancer datasets.
Preparing breast cancer datasets
We collected five independent microarray gene expression datasets generated for study-
ing breast cancer metastasis. The five datasets were generated by the Affymetrix HG-
U133A platform. The raw .CEL files were downloaded from the GEO website: Paw-
itan (GSE1456), Wang (GSE2034), Miller (GSE3494), Loi (GSE6532), and Desmedt
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(GSE7390) [43–47], and normalized by RMA [48]. After merging probes by gene sym-
bols and removing probes with no gene symbol, a total of 13,261 unique genes derived
from the 22,283 probes were included in our study. The patients are classified as cases
and controls in the five datasets based on the time of developing distant metastasis. The
patients who were free of metastasis for longer than eight years of survival and follow-
up time were classified as metastasis-free and the patients who developed metastases
within five years were classified as metastasis cases. The number of selected samples
are reported in Table 2.1.
Classification performance
Test Dataset
Training Dataset Method GSE1456 GSE2034 GSE3494 GSE6532 GSE7390
GSE1456
Signed-NP 0.5985 0.6591 0.6480 0.7247
NP 0.5827 0.6544 0.6424 0.6839
Correlation Coefficients 0.6019 0.6600 0.6464 0.7070
GSE2034
Signed-NP 0.7830 0.6183 0.7222 0.7471
NP 0.7874 0.6147 0.7186 0.7398
Correlation Coefficients 0.7832 0.6174 0.7218 0.7361
GSE3494
Signed-NP 0.7940 0.6410 0.6712 0.7492
NP 0.7981 0.6334 0.6699 0.7311
Correlation Coefficients 0.7841 0.6165 0.6641 0.7209
GSE6532
Signed-NP 0.7940 0.6332 0.6576 0.7380
NP 0.7867 0.6001 0.6409 0.6807
Correlation Coefficients 0.7840 0.6298 0.6481 0.7006
GSE7390
Signed-NP 0.8103 0.6357 0.6672 0.6573
NP 0.8077 0.6177 0.6629 0.6510
Correlation Coefficients 0.8150 0.6232 0.6614 0.6592
Random 0.7475 0.6118 0.5883 0.6264 0.6229
Table 2.2: Evaluating marker genes across breast cancer datasets. Markers selected on
the training dataset are used as features in the cross-validation on the test dataset. The
best results are bold.
We applied Signed-NP, network propagation (NP), and Pearson’s correlation coef-
ficient (CC) to identify markers from each of the five breast cancer datasets. To test
NP on a graph with positively weighted edges the network was constructed by setting
the weights of the edges to the absolute value of the Pearson’s correlation coefficients
between the gene pairs and the vertices were initialized by the Pearson’s correlation coef-
ficients between gene expressions and the case/control labeling. To evaluate the predic-
tive power of the marker genes we performed a cross-dataset validation. Specifically, we
selected the markers genes for Signed-NP and CC from the top 50 up-regulated and 50
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down-regulated genes and from the top 100 genes for NP from the training dataset, and
evaluated the marker genes on the remaining datasets as test sets. The gene expressions
of the marker genes were used as features for cross-validation on the test dataset. We
evaluated the classification performance using a Support Vector Machine (SVM) [49]
with an RBF kernel. Classification performance was evaluated using a receiver oper-
ating characteristic (ROC) score [50]. We reported the mean of the ROC score after
repeating 100 times five fold cross validation. We compared the predictive power of the
marker genes selected by Signed-NP, NP, and CC. To add a random baseline, we also
randomly selected 100 genes and tested with five-fold cross-validation 1000 times. The
results are reported in Table 2.2 with α = 0.5 for Signed-NP where the bold numbers
represent the best ROC score by the three methods. Signed-NP outperformed both NP
and CC in 14 out of 20 cases and NP alone in 18 cases. Signed-NP is clearly more
capable of selecting more predictive marker genes in the experiments.
Consistency of marker genes across datasets
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Figure 2.3: Marker gene consistency across five breast cancer gene list. The
x-axis is the number of selected marker genes ranked by each method. The y-axis is the
percentage of the overlapped genes between the selected markers across at least three
of the breast cancer datasets.
To measure how consistent the selected marker genes are across the five independent
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datasets, we report the percentage of common genes identified by a method in the rank
lists from the datasets. This measurement assumes that the true marker genes are more
likely to be selected in each dataset than the other genes. Thus, higher consistency
across the datasets might indicate higher quality in gene marker selection. We plot the
percentage of common genes among the first k (up to 1000) genes in the gene ranking
lists from at least three of the datasets. We show the results of up-regulated genes in
Figure 2.3. The network propagation method Signed-NP with parameter α = 0.5 clearly
identifies significantly more reproducible marker genes than CC. For example, Signed-
NP identified 31 common genes among the first 100 genes in the gene ranking lists and
CC only identified 24 common genes since CC only considers each feature independently.
NP produced similar consistency in the marker genes compared with Signed-NP since
both NP and Signed-NP capture the more conserved gene co-expressions.
PPI subnetworks and enriched GO terms.
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Figure 2.4: Protein-Protein interaction subnetworks of signature genes iden-
tified by Signed-NP and Correlation Coefficients on the Desmedt dataset.
(A) The PPI subnetworks identified by Signed-NP. (B) The PPI subnetworks identified
by Correlation Coefficients.
The top 100 marker genes identified by Signed-NP and CC in the Desmedt (GSE7390)
[47] dataset were mapped to the human protein-protein interaction (PPI) network
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obtained from HPRD [10] and also analyzed with the DAVID functional annotation
tool [51]. We report the densely connected PPI subnetworks constructed from the top
100 up-regulated genes selected by Signed-NP in Figure 2.4(A). The subnetwork con-
tains 37 genes and 43 connections between the genes. Compared with the PPI subnet-
work generated from the marker genes selected by CC in Figure 2.4(B), which contain
19 genes and 17 connections, the subnetwork is larger and denser. In Figure 2.4(A),
HMMR and RAD51 were reported as oncogenes of breast cancer in Online Mendelian
Inheritance in Man (OMIM) [52], neither of which was detected by CC. Women with a
variation in the HMMR gene had a higher risk of breast cancer even after accounting
for mutations in the BRCA1 or BRCA2 genes. In particular, the risk of breast can-
cer in women under age 40 who carry the HMMR variation was 2.7 times higher than
the risk in women without this variation [53]. RAD51 interacts with the evolutionar-
ily conserved BRC motifs in the human breast cancer susceptibility gene BRCA2 [54].
In addition, the genes MAD2L1, RAD51, AURKA, BRCA1, BUB1, BUB1B, CDT1,
and PTTG1 are listed on the breast cancer gene list in Genetic Association Database
(GAD) [55]. Furthermore, the 37 marker genes in the subnetwork are also enriched by
cell cycle process, nuclear division, DNA replication, DNA metabolic process, and ATP
binding, all of which are well-known cancer relevant GO functions.
The top 100 signature genes identified by Signed-NP enriched 83 GO functions (p-
value¡0.01) and the ones identified by CC only enriched 47 GO functions. The most
significantly enriched GO functions are listed in Table 2.3. It is clear that Signed-NP
identified signature genes that are more functionally coherent.
2.3.2 Genomic Feature Selection on Sample-feature Bipartite Graphs
Data Preparation
We prepared two microarray gene expression datasets [1,2] to study breast cancer metas-
tasis and one arrayCGH dataset to study bladder cancer [56]. The dataset (Rosetta)
in [2] measures expression profiles of 24,481 genes generated by Agilent oligonucleotide
Hu25K microarrays. This dataset contains 97 patient samples among which 51 patients
were free of disease after their diagnosis for an interval of at least 5 years (good outcome)
and 46 patients had developed distant metastasis within 5 years (poor outcome). The
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GO terms Signed-NP
Correlation
Coefficients
cell cycle 38.382 21.419
cell cycle process 34.078 19.295
cell cycle phase 32.805 17.377
M phase 32.329 17.547
mitotic cell cycle 31.849 17.468
mitosis 27.777 15.157
nuclear division 27.777 15.157
M phase of mitotic cell cycle 27.534 14.994
organelle fission 27.236 14.794
cell division 19.805 12.449
organelle organization 19.072 13.072
spindle 18.723 12.557
microtubule cytoskeleton 14.743 X
chromosome 14.389 X
nuclear part 14.028 X
regulation of cell cycle 13.611 X
cellular component organization 13.389 X
DNA replication 12.282 X
intracellular non-membrane-bounded organelle 12.091 X
non-membrane-bounded organelle 12.091 X
intracellular organelle part 11.667 X
organelle part 11.530 X
condensed chromosome 10.774 X
nucleus 10.529 X
chromosomal part 10.397 X
Table 2.3: Enriched GO terms by the signature genes. The p-values in −log10
scale are shown for the enriched GO terms. A “X” denotes a p-value larger than
1× 10−10.
Vijver [1] dataset contains microarray gene expressions produced by the same technique
for generating the Rosetta dataset on 295 samples (194 with good outcome and 101
with poor outcome). The two datasets were chosen for the experiment because Agilent
array data by default report up/down-gene expression with positive and negative values
for testing Signed-NPBi. The RMA normalized Affymetrix arrays used in the previous
experiments usually contain absolute intensities. To avoid additional processing of the
data, the five Affymetrix datasets were not used in this experiment. The arrayCGH
dataset Blaveri [56] was generated with a HumanArray 2.0 array consisting of 2,464
probes at 1.5Mb resolution. After pruning, the dataset contained 98 samples and 2,142
probes. We classified the patient samples by the tumor stage.
Signed-NPBi was compared against SVM with linear and RBF kernels and the
bipartite network propagation algorithm (NPBi) [41]. To apply NPBi, each feature in
the datasets was split into two features to represent the positive portion and the negative
portion in the original features. The parameter α for both Signed-NPBi and NPBi was
chosen from {0.95, 0.5, 0.1} in the analysis.
24
Algorithm Rosetta Vijver
Signed-NPBi 0.7374 0.6682
NPBi 0.7290 0.6162
SVM(linear) 0.7072 0.6708
SVM(RBF) 0.7030 0.6830
Table 2.4: The mean AUC scores of classifying patients with good/poor prognosis in
the Rosetta and Vijver gene expression datasets.
Classification of gene expressions
Signed-NPBi was tested on the two breast cancer gene expression datasets. We per-
formed four-fold cross-validation on each of the two datasets with two folds for training,
one fold for validation, and one fold for testing. We first initialized the patient labels in
the validation fold to zero and combined the training folds to learn the model and tune
the best regularization parameter α. The results on the test fold with the optimal α
are reported to measure the prediction performance. We repeated the four-fold cross-
validation 100 times on each dataset for Signed-NPBi, NPBi, and SVM (linear and RBF
kernel) with the same setting. The mean AUC scores for classifying patients in the test
fold are shown in Table 2.4. The results on the Rosetta dataset in Table 2.4 show that
Signed-NPBi outperformed both NPBi and SVM with linear or RBF kernel. On the
Vijver dataset, Signed-NPBi also performed better than NPBi. Although the SVMs get
better classification performance on Vijver dataset, Signed-NPBi also performed rea-
sonably well. The results support that network propagation on signed bipartite graphs
improved classification over propagation on positively weighted graphs.
Classification of CNV data
Algorithm AUC
Signed-NPBi 0.8654
NPBi 0.8306
SVM(linear) 0.8565
SVM(RBF) 0.8585
Table 2.5: The mean AUCs of classifying patients by tumor stage in the bladder cancer
CNV dataset.
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We then evaluated Signed-NPBi on the bladder cancer CNV dataset (Blaveri). The
cross-validation setup in this experiment was the same as the setup in section 2.3.2.
The mean AUCs are reported in Table 2.5. Signed-NPBi also outperformed NPBi and
SVMs.
Interpretation of CNV Detection with Signed-NPBi
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Figure 2.5: CNV weights learned by Signed-NPBi and Correlation Coefficients
and the CNV data on Chromosome 17.
Finally, we evaluated how well Signed-NPBi smooths the CNV data in order to re-
move noise and identify bi-clusters. Signed-NPBi smooths the weighting of adjacent
probes since the probes in proximity are more likely to be correlated. To demonstrate
the smoothing effect we plot the weights of CNVs on chromosome 17 obtained by Signed-
NPBi and Correlation Coefficients in the top half of Figure 2.5. In the region between
probe index 60-135, CC and Signed-NPBi with α = 0.1 detected low association with
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tumor stage while Signed-NPBi with α = 0.8 and α = 0.95 detected a negative asso-
ciation. By examining the probe log-intensity-ratios across the patients shown in the
bottom half of Figure 2.5, we can confirm an amplification bi-cluster within the negative
group in this region which was not captured by CC or Signed-NPBi with small α. This
example shows the strength of Signed-NPBi to recover hidden bi-clusters in CNV data
by taking into account the dependence between nearby probes.
2.4 Discussion
In this study, we present network propagation models on signed graphs for feature selec-
tion and classification in high-dimensional microarray gene expression and copy number
variation data. Network propagation is a promising approach to explore modular struc-
tures such as clusters or bi-clusters hiding in high-dimensional data. The signed network
propagation models are a useful and important generalization for modeling positive and
negative relations in biological networks.
Since network propagation methods explore graph structures they are usually more
computationally demanding compared with other simpler feature selection methods.
Our future work will focus on developing approximations based on sparse structures to
improve efficiency. In addition, we also plan to further investigate other regularizations
of the signed graph Laplacian to improve the applicability and flexibility of the models.
Chapter 3
Network-based Survival Analysis
on Ovarian Cancer
3.1 Introduction
Survival analysis is routinely applied to analyzing microarray gene expressions to as-
sess cancer outcomes by the time to an event of interest [57–59]. By uncovering the
relationship between gene expression profiles and time to an event such as recurrence
or death, a good survival model is expected to achieve more accurate prognoses or
diagnoses, and in addition, to identify genes that are relevant to or predictive of the
events [60,61]. The Cox proportional hazard model [16] is widely used in survival anal-
ysis because of its intuitive likelihood modeling with both uncensored patient samples
and censored patient samples who are event-free by the last follow-up. Due to the high
dimensionality of typical microarray gene expressions, the Cox regression model is usu-
ally regularized with penalties such as L2 penalty in ridge regression [62–65], L1 Lasso
regularization [26,66–70] and L2 regularization in Hilbert space [71]. While those penal-
ties were designed as a statistical or algorithmic treatment for the high-dimensionality
problem, these Cox models are still prone to noise and overfitting to the low sample
size. An important prior information that has been largely ignored in survival analy-
sis is the modular relations among gene expressions. Groups of genes are co-expressed
under certain conditions or their protein products interact with each other to carry
out a biological function. It has been shown that protein-protein interaction network
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or co-expressions can provide useful prior knowledge to remove statistical randomness
and confounding factors from high-dimensional data for several classification and regres-
sion models [72–75]. The major advantage of these network-based models is the better
generalization across independent studies since the network information is consistent
with the conserved patterns in the gene expression data. For example, previous studies
in [72, 74] discovered that more consistent signature genes of breast cancer metastasis
can be identified from independent gene expression datasets by network-based classifi-
cation models. The observations also motivated several graph algorithms for detecting
cancer causal genes in protein-protein interaction network [76,77].
Figure 3.1: Overview of Net-Cox. The patient gene expression data X and the
survival information specified by followup times t and event indicators δ are illustrated
on the left. The cost function of Net-Cox given in the box combines the total likelihood
of Cox regression with a network regularization. The gene network shown is used as a
constraint to encourage smoothness among correlated genes, i.e. the coefficients of the
genes connected with edges of large weights are similarly weighted.
In this chapter, we propose a network-based Cox proportional hazard model called
29
Net-Cox to explore the co-expression or functional relation among gene expression fea-
tures for survival analysis. The relation between gene expressions are modeled by a gene
relation network constructed by co-expression analysis or prior knowledge of gene func-
tional relations. In the Net-Cox model, a graph Laplacian constraint is introduced as a
smoothness requirement on the gene features linked in the gene relation network. Figure
3.1 illustrates the general framework of Net-Cox for utilizing gene network information
in survival analysis. In the framework, the cost function of Net-Cox, shown in the box,
combines the total likelihood of Cox regression with a network regularization. The total
log-likelihood is a function of the linear regression coefficients β and the base hazard
h0(t) on each followup time {t1, t2, ..., t10}, represented by the likelihood ratios with the
patient gene expression data and the survival information specified by followup times
and event indicators. The gene network is either constructed with gene co-expression
information or a given gene functional linkage network. The gene network is modeled
as a constraint to encourage smoothness among correlated genes, for example gene i
and j in the network, such that the coefficients of the genes connected with edges of
large weights are similarly weighted. The cost function of Net-Cox can be solved by
alternating optimization of β and h0(t) by iterations. An algorithm that solves the
Net-Cox model in its dual representation is also introduced to improve the efficiency.
The complete model is explained in detail in Section 3.3.
In this study, we applied Net-Cox to identify gene expression signatures associated
with the outcomes of death and recurrence in the treatment of ovarian carcinoma.
Ovarian cancer is the fifth-leading cause of cancer death in US women [59]. Identifying
molecular signatures for patient survival or tumor recurrence can potentially improve
diagnosis and prognosis of ovarian cancer. Net-Cox was applied on three large-scale
ovarian cancer gene expression datasets [59, 78, 79] to predict survivals or recurrences
and to identify the genes that may be relevant to the events. Our study is fundamentally
different from previous survival analysis on ovarian cancer [59, 78–80], which are based
on univariate Cox regression. For example, in [59], gene expression profiles from 215
stage II-IV ovarian tumors from TCGA were used to identify a prognostic gene signature
(univariate Cox p−value < 0.01) for overall survival, including 108 genes correlated with
poor (worse) prognosis and 85 genes correlated with good (better) prognosis. In [78], a
Cox score is defined to measure the correlation between gene expression and survival.
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The genes with a Cox score that exceeds an empirically optimized threshold in leave-
one-out cross-validation were reported as signature genes. Similarly, in [79] and [80], a
univariate Cox model was applied to identify association between gene expressions and
survival (univariate Cox p−value < 0.01). Our study is based on gene networks enriched
by co-expression and functional information and thus identifies subnetwork signatures
for predicting survival or recurrence in ovarian cancer treatment.
3.2 Results
In the experiments, Net-Cox was applied to analyze three ovarian cancer gene expres-
sion datasets listed in Table 3.1. Net-Cox (equation (3.4)) was compared with L2−Cox
(equation (3.1)) and L1−Cox (equation (3.2)) with performance evaluation in survival
prediction and gene signature identification for the analysis of patient survival and tu-
mor recurrence. First, for evaluation with a better focus on cancer-relevant genes, the
expressions of a list of 2647 genes that are previously known to be related to cancer
(Sloan-Kettering cancer genes) are used. On the data of these 2647 genes, Net-Cox,
L2−Cox and L1−Cox were evaluated by consistency of signature gene selection across
the three datasets, accuracy of survival prediction and assessment of statistical sig-
nificance. Next, more comprehensive experiments on all 7562 mappable genes were
conducted to identify novel signature genes associated with ovarian cancer. Finally, we
further analyzed and validated ovarian cancer signatures by an additional tumor array
experiment and literature survey. In all the experiments, gene co-expression networks
and a gene functional linkage network were used to derive the network constraints for
Net-Cox. The details of data preparation and the algorithms are described in Section
3.3.
Dataset (GEO ID) TCGA (N/A) Tothill (GSE9899) Bonome (GSE26712)
Death # of Censored 227 160 24
# of Uncensored 277 111 129
Recurrence # of Censored 241 86 N/A
# of Uncensored 263 185 N/A
Table 3.1: Patient samples in the ovarian cancer datasets. The number of pa-
tients categorized by censoring and uncensoring for the death and recurrent events is
reported in each dataset. Note that the Bonome dataset does not provide information
on recurrence.
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3.2.1 Net-Cox identifies consistent signature genes across independent
datasets
To evaluate the generalization of the models, we first measured the consistency among
the signature genes selected from the three independent datasets by each method.
Specifically, we report the percentage of common genes in the three rank lists identified
by a method. This measurement assumes that even under the presence of biological
variability in gene expressions and patient heterogeneities in each dataset, genes that
are selected in multiple datasets are more likely to be true signature genes. Thus, higher
consistency across the datasets might indicate higher quality in gene selection.
Figure 3.2: Consistency of signature genes (Sloan-Kettering cancer genes).
The x-axis is the number of selected signature genes ranked by each method. The y-
axis is the percentage of the overlapped genes between the selected genes across the
ovarian cancer datasets. The plots show the results for the death outcome (A) and the
tumor recurrence outcome (B).
In Figure 3.2, we plot the number of common genes among the first k (up to 300)
genes in the gene ranking lists from all of the three datasets for the death event and
two datasets (TCGA and Tothill) for the recurrence event. For the parameter setting
of Net-Cox, we fixed λ to be the optimal parameter in the five-fold cross-validation (see
Section Materials and Methods and report the results with α = 0.01 and 0.5. Since
the ranking lists of Net-Cox with α = 0.95 are nearly identical to those of L2−Cox, they
are not reported for better clarity in the figure. The first observation is that the gene
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rankings by Net-Cox are more consistent than those by L2−Cox and L1−Cox at all
the cutoffs. Moreover, Net-Cox with α = 0.01 identified more common signature genes
than Net-Cox with α = 0.5. For example, for the tumor recurrence outcome, Net-Cox
(Co-expression) with α = 0.01 and 0.5 identified 36 and 29 common genes among the
first 100 genes in the gene ranking lists, Net-Cox (Functional linkage) with α = 0.01
and 0.5 identified 49 and 23 common genes, and L2−Cox and L1−Cox only identified
19 and 6 common genes, respectively. In general, variable selection by L1−Cox is not
stable from high-dimensional gene expression data, and thus, the overlaps in the gene
lists by L1−Cox are significantly lower than the other methods. It is also interesting
to see the gradient of the overlap ratio from α = 0.01 to α = 0.5, and then to α = 1
(L2−Cox), which indicates that, when a gene network plays more an important role
in gene selection, the gene rankings tend to be more consistent. This observation is
consistent with previous studies with protein-protein interaction network or gene co-
expression network [72, 74, 75]. Note that since the overlaps are across three datasets
for the death event and across two datasets for the recurrence event, the overlaps for
the death event is expected to be lower than those for the recurrence event. Another
important difference is that the same functional linkage network is always used while the
co-expression network is dataset-specific. Thus, it is also expected that the overlaps by
Net-Cox with the functional linkage network is higher than those by Net-Cox with the co-
expression network. Together, the results demonstrate that Net-Cox effectively utilized
the network information to improve gene selection and accordingly, the generalization
of the model to independent data.
3.2.2 Net-Cox improves survival prediction across independent datasets
Test Dataset Net-Cox (Co-exp) Net-Cox (FL) L2−Cox L1−Cox
Death Tothill 1.1178E-06 2.5938E-07 2.9932E-06 0.0011
Bonome 7.6088E-07 3.6039E-06 5.2590E-06 0.1165
Recurrence Tothill 0.0567 0.0786 0.1115 0.4219
Table 3.2: Log-rank test p−values in cross-dataset evaluation (Sloan-Kettering
cancer genes). The survival prediction performance on Tothill and Bonome datasets
using the Cox models trained with TCGA dataset are reported.
Five-fold cross-validation was first conducted for parameter tuning for Net-Cox,
L2−Cox and L1−Cox on each dataset. The optimal parameters of Net-Cox are reported
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Figure 3.3: Cross-dataset survival prediction (Sloan Kettering cancer genes).
The first four columns of plots show the Kaplan-Meier survival curves for the two
risk groups defined by Net-Cox (co-expression network), Net-Cox (functional linkage
network), L2−Cox and L1−Cox. The fifth column of plots compare the time-dependent
area under the ROC acurves based on the estimated risk scores (PIs). The plots show
the results for the death outcome by training with TCGA dataset and test on Tothill
Dataset (A), the death outcome by training with TCGA dataset and test on Bonome
Dataset (B), the tumor recurrence outcome by training with TCGA dataset and test
on Tothill Dataset (C).
in Table S1 in [35]. To test how well the models generalize across the datasets, we trained
Net-Cox model, L2−Cox model, and L1−Cox model with the TCGA dataset, and then
predicted the survival of the patients in the other two datasets with the TCGA-trained
models. In training, we used the optimal λ and α from the five-fold cross-validation
to train the models with the whole TCGA dataset. The results are given in Table
3.2. In all the cases, Net-Cox obtained more significant p−values in the log-rank test
than L2−Cox and L1−Cox. To further compare the results, we show the Kaplan-Meier
survival curves and the ROC curves in Figure 3.3. The first four columns of plots in the
figure show the Kaplan-Meier survival curves for the two risk groups defined by Net-Cox
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with co-expression network and functional linkage network, L2−Cox, and L1−Cox. The
fifth column of plots compare the time-dependent area under the ROC curves based on
the estimated risk scores (PIs). In Figure 3.3, in many regions, Net-Cox achieved large
improvement over both L2−Cox and L1−Cox while the improvement is less obvious
in several other regions. Overall, Net-Cox achieved better or similar AUCs in all the
time points in the three plots. To evaluate the statistical significance of the differences
between the time-dependent AUCs generated by Net-Cox and the other two methods, in
Table S2 in [35] we report p−values at each event time with the null hypothesis that the
two time-dependent AUCs estimated by two models are equal. At many points of the
event time, the time-dependent AUCs generated from Net-Cox are significant higher.
The cross-validation log-partial likelihood (CVPLs) for the combinations of (λ, α)
in the five-fold cross-validation are also reported in Table S3 in [35]. In all the cases,
the optimal CVPLs of Net-Cox are higher than those of L2−Cox. L1−Cox was fine-
tuned with 1000 choices of parameters with a very small bin size. In one of the cases
(TCGA: Recurrence), the optimal CVPL of L1−Cox is higher but in the other cases,
the optimal CVPLs of Net-Cox are higher. Interestingly, the optimal α is often 0.1 or
0.5, indicating the optimal CVPL is a balance of the information from gene expressions
and the network. The observations prove that the network information is useful for
improving survival analysis. The left column of Figure S1 in [35] shows the average
time-dependent area under the ROC curves based on the estimated risk scores (PI) of
the patients in the fifth fold of the five repeats, and Table S4A and S4B in [35] show
log-rank p−values of the fifth fold of the five repeats. Net-Cox achieved the best overall
survival prediction although the results are less obvious than those of the cross-dataset
analysis.
3.2.3 Statistical assessment
To understand the role of the gene network on the consistency in gene selection and
the contribution to the log-partial likelihood, we tested Net-Cox with randomized co-
expression networks. In each randomization, the weighted edges between genes were
shuﬄed. We report the mean and the standard deviation of the percentage of overlap-
ping genes of 50 randomizations in Figure 3.4. Compared with the consistency plots
with the true networks, the overlaps by Net-Cox on the randomized networks are much
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Figure 3.4: Consistency of signature genes on randomized co-expression net-
works. The x-axis is the number of selected signature genes ranked by each method.
The y-axis is the percentage of the overlapped genes between the selected genes across
the ovarian cancer datasets. The red curve reports the mean and the standard deviation
of the percentages averaged over the experiments of 50 randomized networks. The plots
show the results for the death outcome (A) and the tumor recurrence outcome (B).
lower. We also report the boxplot of the log-partial likelihood in the same 50 random-
ized co-expression network with α = 0.01 in Figure 3.5. Compare with the log-partial
likelihood with the real co-expression network, the range of the likelihood generated
with the randomized networks is again lower by a large margin, which provides clear
evidence that the co-expression network is informative for survival analysis.
To further understand the role of the network information in cross-validation, we
fixed the optimal parameter λ and conducted the same five-fold cross-validation with
randomized co-expression networks to compute the CVPL with different α in {0.01, 0.1,
0.5. 0.95}. We repeated the process on 20 random networks for each α. The boxplots of
CVPLs with different αs are shown in Figure 3.6. In all measures, the CVPL with the
true gene network is well above the mean of the 20 random cases. Another important
observation is that, in both plots, when the randomized network information is more
trusted with a smaller α, the variance of the CVPLs is also getting larger; and the
case with α = 0.01 gives the worst CVPL mean and the largest variance. The result
indicates that the randomized networks did not provide any valuable information in
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Figure 3.5: Statistical analysis of log-partial likelihood. The optimal λ was fixed
and α = 0.01 is set to allow better evaluation of the network information. The log-
partial likelihood computed by Net-Cox on the real co-expression network and on the
randomized co-expression network are reported against tumor recurrence in the TCGA
and Tothill datasets. The stars represent the results with the real co-expression net-
works, and the boxplots represent the results with the randomized networks.
survival prediction. In contrast, with the true gene network, CVPLs generated from
α = 0.01 and α = 0.1 are much higher than the ones from α = 0.95 and L2−Cox
(α = 1). Again, these results convincingly support the importance of using the network
information in survival prediction.
3.2.4 Evaluation by whole gene expression data
Besides the 2647 Sloan-Kettering genes, all the 7562 mappable genes were also tested
to evaluate Net-Cox, L2−Cox and L1−Cox by consistency of signature gene selection
across the three datasets and accuracy of survival prediction in similar experiments.
For the signature gene consistency, Figure S2 in [35] reports the percentage of common
genes identified by each method in the ranking lists from the datasets. For the cross-
dataset validation, Table S5 in [35] shows the log-rank test p−values by training the
TCGA datasets and test on the other two datasets, and Figure S3 in [35] shows the
Kaplan-Meier survival curves for the two risk groups defined by Net-Cox, L2−Cox
and L1−Cox and compares the time-dependent area under the ROC curves. For the
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Figure 3.6: Statistical analysis of cross-validation log-partial likelihood
(CVPL). The optimal λ was fixed and α is varied from 0.01 to 1. The CVPL of
five-fold cross-validation on the real co-expression network and on the randomized co-
expression network are reported against tumor recurrence in TCGA dataset (A) and
Tothill dataset (B). The stars represent the results with the real co-expression networks,
and the boxplots represent the results with the randomized networks.
five-fold cross-validation, the right column of Figure S1 in [35] shows the average time-
dependent area under the ROC curves based on the estimated risk scores (PI) of the
patients in the fifth fold of the five repeats, and Table S4C and S4D in [35] report log-
rank test p−values of the fifth fold of the five repeats. Overall, similar observations are
made in experimenting with all the genes, though the improvements are less significant
compared with the results by experimenting with the Sloan-Kettering cancer genes. One
possible explanation is that, since the genes in the Sloan-Kettering gene list are more
cancer relevant, the gene expressions may be more readily integrated with the network
information.
3.2.5 Signature genes are ECM components or modulators
To analyze the signature genes identified by Net-Cox and L2−Cox, we created consensus
rankings across the three datasets by re-ranking the genes with the lowest rank by Net-
Cox and L2−Cox in the three datasets. Specifically, for each gene, a new ranking score
is assigned as the lowest of its ranks in the three datasets, and then, all the genes were
re-ranked by the new ranking score. The top-15 genes selected by Net-Cox and L2−Cox
in the consensus rankings are shown in Table 3.3. For the death outcome, nine signature
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Death Recurrence
Net-Cox (Co-exp) Net-Cox (FL) L2−Cox Net-Cox (Co-exp) Net-Cox (FL) L2−Cox
FBN1 COL11A1 COL11A1 COL5A2 COL11A1 COL11A1
COL5A2 MFAP4 FABP4 COL1A1 COL10A1 NLRP2
VCAN TIMP3 MFAP4 COL5A1 CRYAB CRYAB
SPARC MFAP5 COMP THBS2 NPY PTX3
AEBP1 COL5A2 BCHE FAP IGF1 COL10A1
AOC3 THBS2 FAP COL3A1 COMP CXCL12
COL3A1 FAP COL5A2 COL11A1 KLK5 THBS2
THBS2 CXCL12 MFAP5 FBN1 THBS2 NPY
PLN AEBP1 TIMP3 VCAN PI3 KLK5
ADIPOQ RYR3 THBS2 INHBA CXCL12 COMP
COL5A1 LOX HOXA5 CTSK MFAP5 FAP
CNN1 COL5A1 NUAK1 COL1A2 VGLL1 MFAP5
COL6A2 EDNRA COL5A1 SPARC CCL11 PI3
COL1A2 NUAK1 SLIT2 AEBP1 EPHB1 PDGFD
DCN LPL CXCL12 SERPINE1 OXTR CHRDL1
Table 3.3: Top-15 signature genes. The table lists the genes with over-expression
indicating higher hazard of death or recurrence, identified by Net-Cox and L2−Cox in
the consensus ranking across the three datasets.
genes, FBN1, VCAN, SPARC, ADIPOQ, CNN1, DCN, LOX, EDNRA, LPL, known to
be related to ovarian cancer [81–89] are only discovered by Net-Cox. Among the ten
common genes highly ranked by both Net-Cox and L2−Cox, three are collagen genes,
and MFAP5, TIMP3, THBS2, and CXCL12 are previously known to be relevant to
ovarian cancer [90–93]. For the recurrence outcome, there are eleven common signature
genes detected by both Net-Cox and L2−Cox. Net-Cox identified six additional ovarian
cancer related signature genes [81–83,94–96].
Gene Sym Reference Description
ADIPOQ [84] ADIPOQ 45T/G and 276G/T polymorphisms is associated with susceptibility to polycystic ovary syndrome(PCOS).
CCL11 [96] CCL11 signaling plays an important role in proliferation and invasion of ovarian carcinoma cells.
CNN1 [85] CCN1 plays a role in ovarian carcinogenesis by stimulating survival and antiapoptotic signaling pathways.
CRYAB [97] Low expression of lens crystallin CRYAB is significantly associated with adverse ovarian patient survival.
CXCL12 [93] CXCL12 and vascular endothelial growth factor synergistically induce neoangiogenesis in human ovarian cancers.
DCN [86] Ovarian DCN is an ECM-associated component, which acts as a multifunctional regulator of GF signaling in the primate ovary.
EDNRA [88] Endothelin peptide is produced before ovulation and the contractile action of EDN2 within the ovary is facilitated via EDNRA.
FBN1 [81] FBN1 controls the bioactivity of TGFβs and associate with polycystic ovary syndrome (PCOS).
IGF1 [95] Ovarian follicular growth is controlled by the production of intraovarian growth regulatory factors such as IGF1.
INHBA [94] INHBA is the promoter of TAF4B; TAF4B in the ovary is essential for proper follicle development.
LOX [87] Inhibition of LOX expression portends worse clinical parameters for ovarian cancer.
LPL [89] LPL is differentially expressed between preoperative samples of ovarian cancer patients and those of healthy controls.
MFAP5 [90] MAGP2 is an independent predictor of survival in advanced serous ovarian cancer.
NPY [98] NPY receptor is expressed in human primary ovarian neoplasms.
SPARC [83] SPARC expression in ovarian cancer cells is inversely correlated with the degree of malignancy.
THBS2 [92] In ovarian cancer an aberrant methylation process is responsible for down-regulation of THBS2.
TIMP3 [91] TIMP2 and TIMP3 play functional role in LPA-induced invasion as negative regulators.
VCAN [82] VCAN V1 isoform is overexpressed in ovarian cancer stroma compared with normal ovarian stroma and ovarian cancer cells.
Table 3.4: Literature review of the candidate ovarian cancer genes. This table
reports the citations that describe relevance of the signature genes with over-expression
indicating higher hazard of death or recurrence, identified by Net-Cox across the three
datasets.
The intersection of the 60 genes identified by Net-Cox in Table 3.3 contains 41
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unique genes. We performed a literature survey of the 41 genes, out of which eigh-
teen are supported by literature to be related to ovarian cancer shown in Table 3.4.
Most of the genes whose over-expression is associated with poor outcome are stromal
or extracellular-related proteins. The genes such as VCAN, TIMP3, THBS2, ADIPOQ,
PARC, NPY, MFAP5, DCN, LOX, FBN1, EDNRA, and CXCL12 are either compo-
nents or modulators of extracellular matrix. In particular, LOX protein is involved in
extracellular matrix remodeling by cross-linking collagens. Extracellular matrix remod-
eling through over-expression of collagens has been shown to contribute to platinum
resistance, and platinum resistance is the main factor in chemotherapy failure and poor
survival of ovarian cancer patients. Therefore, the identification of these extracellular
matrix proteins as biomarkers of early recurrence and poor survival outcome in patients
with ovarian cancer is consistent with the suggested pathobiological role of some of these
proteins in platinum resistance.
3.2.6 Enriched PPI subnetworks and GO terms
The top-100 signature genes with the largest regression coefficients by Net-Cox and
L2−Cox learned from the TCGA dataset were mapped to the human protein-protein
interaction (PPI) network obtained from HPRD [10] and also analyzed with DAVID
functional annotation tool [51]. We report the densely connected PPI subnetworks con-
structed from the 100 genes selected by Net-Cox in Figure 3.7. Compared with the PPI
subnetworks generated from the 100 genes selected by L2−Cox, which contain 10 genes
in the death subnetwork and 6 genes in the recurrence subnetworks (shown in Figure
S4 in [35]), the subnetworks are both larger and denser. The subnetworks identified
from the co-expression networks in Figure 3.7(A) are also larger than the subnetworks
identified by the functional linkage network in Figure 3.7(B) although many genes are
shared. In the recurrence subnetworks, DCN, THBS1, and THBS2 are members of the
TGF−β signaling KEGG pathway, and FBN1 controls the bioactivity of TGFβs and
relates to polycystic ovary syndrome [81]. In addition, ten genes are members of the
focal adhesion KEGG pathway. These results point to a possibility that extracellular
matrix signaling through focal adhesion complexes may constitute a pathway by which
tumor cells escape chemotherapy and produce recurrence in chemotherapy [99]. Nine
genes in the death subnetworks are members of the extracellular matrix(ECM)-receptor
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Figure 3.7: Protein-Protein interaction subnetworks of signature genes iden-
tified by Net-Cox on the TCGA dataset. (A) The PPI subnetworks identified by
Net-Cox on the co-expression network. (B) The PPI subnetworks identified by Net-Cox
on the functional linkage network.
interaction KEGG pathway, and eighteen genes are annotated as ECM component. It
was shown that ECM acts as a model substratum for the preferential attachment of
human ovarian tumor cells in vitro [100]. FOS and JUN constitutes a nuclear signal-
ing components downstream of extracellular signal-regulated kinases (ERK1/2) that
are mediators of growth factor and adhesion-related signaling pathways [101]. In addi-
tion, the genes are also enriched by regulation of gene expression, positive regulation
of cellular process, developmental process, transcription regulator activity, and growth
factor binding, all of which are well-known cancer relevant functions. The significantly
enriched GO functions are listed in Table S6 and Table S7 in [35]. Extracellular matrix,
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extracellular region, and extracellular structure organization are consistently the most
significantly enriched in the analysis.
3.2.7 Laboratory experiment validates FBN1’s role in chemo-resistance
FBN1 was ranked 1st and 8th by Net-Cox with co-expression network in death and re-
currence outcomes while L2−Cox only ranked FBN1 at 27th and 42nd, respectively. It
is interesting to note that in the PPI subnetworks in Figure 3.7(A), FBN1 is connected
with VCAN and DCN, both of which bear the annotation of extracellular matrix. The
dense subnetwork boosted the ranking of FBN1 when Net-Cox was applied. We fur-
ther validated the role of FBN1 in ovarian cancer recurrence using tumor microarrays
(TMAs) consisting of a cohort of 78 independent patients (see Section Materials and
Methods). The expression level of FBN1 in ovarian cancer was scored by one observer
who is blinded to the clinical outcome and described as: absent (0), moderate (1), and
high (2) as illustrated by Figure 3.8.
Figure 3.8: Representative photomicrographs showing various levels of FBN1
expression in ovarian tumor arrays. The brown regions are stromal area showing
expression of FBN1.
In Figure S5A in [35], the Kaplan-Meier survival curve shows the recurrence for
groups by the FBN1 staining scores. At the initial 12 month, there is no difference in
the recurrence rate between the groups with high and low FBN1 staining. After 12
month, the recurrence rate is lower in the low staining group. The similar patterns are
also observed in the re-examination of the gene expression datasets in Figure S5B-E
in [35]. Except the TCGA dataset on the Affymetrix platform (Figure S5E in [35]),
the pattern is clearly observed on the other two platforms, exon arrays and Agilent
arrays. The discrepancy in the Affymetrix data could be related to data pre-processing
or experimental noise. The plots suggest that FBN1 plays a role on platinum-sensitive
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ovarian cancer, and it could be developed as a target for platinum-sensitive patients
with high FBN1 expression after about 12 month of the treatment.
In the context of ovarian cancer treatment, a platinum-sensitive patient group can
be defined as the group of patients who was free of recurrence or developed a recurrence
after k month of the treatment, where k ≥ 14 depends on the treatment plan and the
follow-up. To better evaluate the role of FBN1, we plot the Kaplan-Meier survival curve
only for the platinum-sensitive patients in Figure 3.9, i.e. we removed all the patients
who developed recurrence before k month and considered the follow-ups up to 72 month
after the treatment. Due to the small sample size of the Mayo Clinic data, we set k = 14
while k = 20 for the gene expression datasets. In Figure 3.9A, the difference between the
survival curves of low FBN1 staining and high staining patient groups is more significant.
Similarly, Figure 3.9B-E show the survival curves for the platinum-sensitive patients
for groups by the expression value of FBN1 in gene expression datasets. Compare to
the matched curves in Figure S5 in [35], the log-rank test p−values are more significant
except the TCGA dataset on the Affymetrix platform. Overall, the observations strongly
support the hypothesized role of FBN1 in platinum-sensitive ovarian cancer patients.
3.3 Materials and Methods
3.3.1 Gene relation network construction
We denote gene relation network by G = (V ,W ), where V is the vertex set, each
element of which represents a gene, and W is a |V |× |V | positively weighted adjacency
matrix. D is a diagonal matrix with Dii =
∑
jWij and S = D
− 1
2WD−
1
2 is the
normalized weighted adjacency matrix by dividing the square root of the column sum
and the row sum. Two gene relation networks were used with Net-Cox, the gene co-
expression network and the gene functional linkage network.
Gene co-expression network: A gene co-expression network was generated from a gene
correlation graph model. In the weighted adjacency matrixW , each Wij is the reliability
score [102] based on the absolute value of the Pearson’s correlation coefficients between
genes vi and vj , calculated as Wij =
1
Ri,j×Rj,i , where Ri,j is gene vi’s rank among all
the genes with respect to the correlation with gene vj and Rj,i is gene vj ’s rank with
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Figure 3.9: Kaplan-Meier survival plots on FBN1 expression groups. (A)
Kaplan-Meier survival curve of recurrence between 14 to 72 month by FBN1 staining
groups on Mayo Clinic dataset. (B) Kaplan-Meier survival curve of recurrence between
20 to 72 month by the expression of FBN1 on Tothill dataset. (C)-(E) Kaplan-Meier
survival curves of recurrence between 20 to 72 month by the expression of FBN1 on
TCGA dataset with AgilentG4502A platform, HuEx-1 0-st-v2 platform, and Affymetrix
HG-U133A platform, respectively. In plot(A), the groups with FBN1 staining score 1
and 2 are combined into the high-expression group. In plots(B)-(E), the patients are
divided into two groups of the same size by the expression of FBN1.
respect to the correlation with gene vi. Note that the gene co-expression network is
directly inferred from the gene expression dataset. Thus, a gene co-expression network
is specific to the dataset used for computing the co-expression network.
Gene functional linkage network: A human gene functional linkage network was con-
structed by a regularized Bayesian integration system [103]. The network contains maps
of functional activity and interaction networks in over 200 areas of human cellular bi-
ology with information from 30,000 genome-scale experiments. The functional linkage
network summarizes information from a variety of biologically informative perspectives:
prediction of protein function and functional modules, cross-talk among biological pro-
cesses, and association of novel genes and pathways with known genetic disorders [103].
Each edge in the network is weighted between [0,1] to quantify the functional relation
between two genes. Thus, the functional linkage network provides much more compre-
hensive information than Human protein-protein interaction network, which was more
frequently used as the network prior knowledge.
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3.3.2 Gene expression dataset preparation
Three independent microarray gene expression datasets for studying ovarian carcinoma
were used in the experiments [59, 78, 79]. The information of patient samples in each
dataset is given in Table 3.1. All the three datasets were generated by the Affymetrix
HG-U133A platform. The raw .CEL files of two datasets were downloaded from GEO
website (Tothill: GSE9899) and (Bonome: GSE26712) [78, 79]. The TCGA dataset
was downloaded from The Cancer Genome Atlas data portal [59]. The raw files were
normalized by RMA [48]. After merging probes by gene symbols and removing probes
with no gene symbol, a total of 7562 unique genes were derived from the 22,283 probes
and overlapped with the functional linkage network for this study. Note that the Bonome
dataset does not provide information on recurrence. Thus, only TCGA and Tothill
datasets were used for studying recurrence while all the three datasets were used for
studying death. In cross-dataset validation, the batch effects among the three datasets
were removed by applying ComBat [104]. Besides testing all the genes, for a better
focus on genes that are more likely to be cancer relevant, we derived a set of 2647 genes
from the cancer gene list compiled by Sloan-Kettering Cancer Center (SKCC) [105].
The TCGA datasets with AgilentG4502A platform (gene expression array) and
HuEx-1 0-st-v2 (exon expression array) were used to evaluate the signature gene FBN1
in Figure 3.9. The processed level 3 data with expression calls for gene/exon were
downloaded from the TCGA data portal.
3.3.3 Cox proportional hazard model
In the analysis of microarray gene expressions, the number of gene features p is larger
than the number of subjects n by several magnitudes (pn). Fitting the Cox regression
model proposed in section 1.2.2 will lead to large regression coefficients, which are not
reliable. One possible solution is to introduce a L2−norm constraint to shrink regres-
sion coefficients estimates towards zero [62, 65]. In the L2−Cox model, the regression
coefficients are estimated by maximizing the penalized total log-likelihood:
lpen(β, h0) =
n∑
i=1
{−exp(X ′iβ)H0(ti) + δi [log(h0(ti)) +X ′iβ]}− 12λ
p∑
j=1
βj
2, (3.1)
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where λ
∑p
j=1 βj
2 is the penalty term and λ is the parameter controlling the amount
of shrinkage. Another possibility is to introduce a L1−norm constraint for variable
selection [26, 66]. The L1−Cox model penalizes the log-partial likelihood (equation
(1.3)) by λ
∑p
j=1 |βj | leading to:
plpen(β) =
n∑
i=1
δi
X ′iβ − log
 ∑
j∈R(ti)
exp(X ′jβ)
− λ
p∑
j=1
|βj |. (3.2)
In our experiments, R package “glmnet” [106] was used in the implementation of
L1−Cox.
3.3.4 Network-constrained Cox regression (Net-Cox)
We introduce a network-constraint to the Cox model as follows,
lpen(β, h0) = l(β, h0)− 1
2
λβ′[(1− α)L+ αI]β, (3.3)
where L is a positive semidefinite matrix derived from network information, I is an
identity matrix, and λ is the parameter controlling the weighting between the total
likelihood and the network constraint. α ∈ (0, 1] is another parameter weighting the
network matrix and the identity matrix in the network constraint. For convenience, we
define Γ = (1− α)L+ αI and rewrite the object function as
lpen(β, h0) =
n∑
i=1
{−exp(X ′iβ)H0(ti) + δi [log(h0(ti)) +X ′iβ]}− 12λβ′Γβ. (3.4)
The term λβ′[(1− α)L+ αI]β in equation (3.3) is a network Laplacian constraint to
encode prior knowledge from a network. Given a normalized graph weight matrix S,
we assume that co-expressed (related) genes should be assigned similar coefficients by
defining the following cost term over the coefficients,
Ψ(β) =
1
2
p∑
i,j=1
Si,j(βi − βj)2
= β′(I − S)β = β′Lβ. (3.5)
As illustrated in Figure 3.1, the Laplacian constraint encourages a smoothness among
the regression coefficients in the network. Specifically, for any pair of genes connected
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by an edge, there is a cost proportional to both the difference in the coefficients and
the edge weight. Large difference between coefficients on two genes connected with a
highly weighted edge will result in a large cost in the objective function. Thus, the
objective function encourages assigning similar weights to genes connected by edges of
larger weights. By adding an additional L2−norm constraint to Ψ(β) weighted by α,
we obtain the network constraint (1 − α)β′Lβ + α|β|2=β′Γβ in equation (3.3) and
(3.4). The L2−norm of β similarly regularizes the uncertainty in the network con-
straint, which could have a singular Hessian matrix, and the α parameter balances
between the L2−norm and the “Laplacian-norm”. The smaller the α parameter, the
more importance put on the network information.
3.3.5 Alternating optimization algorithm
The objective function defined by equation (3.4) can be solved by alternating optimiza-
tion of β and h0(t). The maximization with respect to β is done by Newton-Raphson
method. The derivative of equation (3.4) is
∂lpen(β, h0)
∂β
=
n∑
i=1
[
δi − exp(X ′iβ)H0(ti)
]
Xi − λΓβ
= X′∆− λΓβ, (3.6)
where ∆i = δi − exp(X ′iβ)H0(ti), and the second derivative is
∂2lpen(β, h0)
∂β∂β′
= −
[
n∑
i=1
exp(X ′iβ)H0(ti)XiX
′
i
]
− λΓ
= −X′DX − λΓ, (3.7)
where D is the diagonal matrix with Dii = exp(X
′
iβ)H0(ti). Thus, the full algorithm
to solve the Net-Cox model is given below.
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1 Initialization: β = 0; Compute L = I − S.
2 Do until convergence
(a) Do Newton-Raphson iteration
i. Compute the first derivative l′pen(β, h0) =
∂lpen(β,h0)
∂β
ii. Compute the second derivative l′′pen(β, h0) =
∂2lpen(β,h0)
∂β∂β′
iii. Update β = β − {l′′pen(β, h0)}−1l′pen(β, h0)
(b) Update hˆ0(ti) = 1/
∑
j∈R(ti) exp(X
′
jβˆ)
3 Return β
Using Newton-Raphson method to update β requires inverting the Hessian matrix,
which is time consuming and often inaccurate. An alternative approach is to reduce the
covariant space from p to n, which relates to singular value decomposition that exploits
the low rank of the gene expression matrix X [65]. The equation
∂lpen(β, h0)
∂β
=
n∑
i=1
[
δi − exp(X ′iβ)H0(ti)
]
Xi − λΓβ
= X′∆− λΓβ = 0 (3.8)
implies that β = Γ−1X ′η for some η. Thus, the dual form of equation (3.4) with
respect to η is
lpen(η, h0) =
n∑
i=1
{−exp(Z ′iη)H0(ti) + δi [log(h0(ti)) +Z ′iη]}− 12λη′Zη (3.9)
with Zi = XΓ
−1Xi and Z = XΓ−1X′. In its dual form, it is clear that the new object
function (3.9) is equivalent to equation (3.4) but the problem dimension is reduced from
p to n.
3.3.6 Cross validation and parameter tuning
To determine the optimal tuning parameters λ and α, we performed five-fold cross-
validation following the procedure proposed by [65] on each of the three datasets. In
the cross-validation, four folds of data are used to build a model for validation on the
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fifth fold, cycling through each of the five folds in turn, and then the (λ, α) pair that
maximizes the cross-validation log-partial likelihood (CVPL) are chosen as the optimal
parameters. CVPL is defined as
CV PL(λ, α) =
5∑
i=1
[
pl(βˆ
(−i)
(λ,α))− pl(−i)(βˆ
(−i)
(λ,α))
]
(3.10)
where βˆ(−i) is the optimal β learned from the data without the ith fold. In the equation,
pl() denotes the log-partial likelihood on all the samples and pl(−i)() denotes the log-
partial likelihood on samples excluding the ith fold. We performed a grid search for the
optimal (λ, α) maximizing the sum of the contributions of each fold to the log-partial
likelihood in CVPL. In particular, λ was chosen from {1e-5, 1e-4, 1e-3, 1e-2, 1e-1, 1}
(λs larger than 1 do not change the ranking of β anymore), and α was chosen from
{0.01, 0.1, 0.5, 0.95}. Note that, when α = 1, Net-Cox ignores the network information
and is reduced to L2−Cox. For L1−Cox, the optimal λ was chosen from 1000 λs by the
“glmnet” parameter setting with the largest CVPL.
3.3.7 Evaluation measures
The Log-rank test [107] and time-dependent ROC [108] were used to evaluate mea-
surements of the prediction performance by a survival model. For the gene expression
profile X in the test set, the prognostic indexes PI=X′βˆ is computed, where βˆ is the
regression coefficients of the survival model, to rank the patients by descending order.
We assigned the top 40% of the patients as the high-risk group and the bottom 40% as
the low-risk group.
The Log-rank test is a statistical hypothesis test for comparison of two Kaplan-
Meier survival curves with the null hypothesis that there is no difference between the
population survival curves, i.e. the probability of an event occurring at any time point
is the same for each population. The test statistic is compared with a χ2 distribution
with one degree of freedom to derive the significance p−value reflecting the difference
between two survival curves. The log-rank test only evaluates whether the patients
are assigned to the “right group” but not how well the patients are ranked within the
group by examining the PI. A more refined approach is afforded by the time-dependent
ROC curves [108,109]. Time-dependent ROC curves evaluate how well the PI classifies
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the patients into high-risk and low-risk prognosis groups. Letting f(X)=X′βˆ, we can
define time-dependent sensitivity and specificity functions at a cutoff point c as
sensitivity[c, t|f(X)] = Pr {f(X) > c|δ(t) = 1} ,
specificity[c, t|f(X)] = Pr {f(X) ≤ c|δ(t) = 0}
with δ(t) being the event indicator at time t [109]. The corresponding ROC curve for any
time t, ROC[t|f(X)], is the plot of sensitivity[c, t|f(X)] versus 1−specificity[c, t|f(X)]
with different cutoff point c. AUC[t|f(X)] is denoted as the area under theROC[t|f(X)]
curve. A larger AUC[t|f(X)] indicates better prediction of time to event at time t, as
measured by sensitivity and specificity evaluated at time t. We plot the AUCs at each
time t to compare the methods.
To select gene variables in the multi-variate scenario by Net-Cox and L2−Cox, we
ranked the genes by the magnitude of the coefficients β. To justify this simple ranking
method, we examined the relation between the magnitude of the coefficients for each
gene and the contribution of the gene to the log-partial likelihood in Figure S6 in [35].
It is clear in the plot that the genes towards the two tails of the ranking list contributes
most of the likelihood, and the proportion of the contributions are consistent with the
ranking. For L1−Cox, we ranked the genes by the first-time jump into the active set
when decreasing the tuning parameter λ in the solution path.
3.3.8 Tumor array preparation
With approval by the Mayo Clinic Institutional Review Board, archived ovarian ep-
ithelial tumor specimens from patients with advanced-stage, high-grade serous, or en-
dometrioid tumors obtained prior to exposure to any chemotherapy were utilized to
construct the TMA array. The array was constructed using a custom-fabricated device
that utilizes a 0.6-mm tissue corer and a 240-capacity recipient block. Triplicate cores
from each tumor were included, as were cores of liver as fiducial markers and controls
for immunohistochemistry reactions. Five-micrometer-thick sections were cut from the
TMA blocks. Immunohistochemistry was performed essentially as described in [110].
Sections of tissue arrays were deparaffinized, rehydrated, and submitted to antigen re-
trieval by a steamer for 25 minutes in target retrieval solution (Dako, Carpinteria, CA,
USA). Endogenous peroxide was diminished with 3% H2O2 for 30 min. Slides were
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blocked in protein block solution for 30 min and then blocked with avidin and biotin
for 10 min each, followed by overnight incubation with 1:1000 diluted Anti-FBN1 an-
tibody (HPA021057, Sigma-Aldrich) at 4◦C. The sections were then incubated with
biotinylated universal link for 15 min and streptavidin for 25 min at 25◦C. Slides were
developed in diaminobenzine and counterstained with hematoxylin.
3.4 Discussion
Many methods were proposed for survival analysis on high-dimensional gene expression
data with highly correlated variates [60, 61]. In this study, we propose Net-Cox, a
network-based survival model, which to our knowledge is among the first models that
directly incorporate network information in survival analysis. The graph Laplacian
constraint introduced in Net-Cox is positive definite and thus, the Net-Cox model can
be solved as efficiently as solving the L2−Cox model. In the dual form of Net-Cox,
the model is scalable to genomic data with p  n. Net-Cox not only makes survival
predictions but also generate densely connected subnetworks enriched by genes with
large regression coefficients.
Net-Cox is most related to the Lp shrinkage-based Cox models typically with L1
(Lasso) and L2 (ridge) penalties [61]. The purpose of applying L1 regularization is to
obtain a sparse estimate of the linear coefficients for solving the high-dimensionality
problem. A Ridge penalty results in small regression coefficients to avoid overfitting
problem with the small sample size. Compared with Net-Cox, neither Lasso nor ridge
regularized Cox regression models are designed to incorporate any prior information
among genes in the objective function for survival analysis. Another alternative solu-
tion in the literature is to apply dimension reduction methods to obtain a small num-
ber of features for subsequent survival analysis such as principal components analysis
(PCA) [111–113] and partial least squares (PLS) [114–117]. These methods first com-
pute the principle components to capture the maximal covariance with the outcomes or
the maximal variance in the gene expression data, and then project the original high-
dimensional gene expressions into a space of the directions of the principle components.
Typically, these methods do not utilize any prior information. It is also usually difficult
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to interpret the results since the features in the project space are not directly map-
pable to any particular gene expression. There are also tree-based ensemble methods
for survival analysis such as bagging of survival trees and random forests [118,119]. The
tree-based methods usually also require a variable selection step to reduce the dimen-
sionality. Multiple trees are then built from different samplings of training data and the
results of the individual trees are aggregated for making predictions. Since the trees are
built from random sampling, the resulted forests consist of different trees. Thus, the
interpretation of the trees can be very difficult [60].
In [120], a supervised group Lasso approach (SGLasso) is proposed to account for
the cluster structure in gene expression data as prior information in survival analysis. In
this approach, gene clusters are first identified with clustering. Important genes are then
identified with Lasso model within each cluster and finally, the clusters are selected with
group Lasso. More recently, the method in [121] combined a group Lasso constraint with
Lasso Cox regression (sparse-group Lasso). An additional parameter is introduced to
balance between Lasso and group Lasso constraints. There are two major discrepancies
between Net-Cox and the graph Lasso methods. First, while group Lasso assumes non-
overlapping cluster structures among gene expressions, the gene network introduced in
Net-Cox captures more global relation among all the genes. Specifically, beyond the
cluster partition of genes into co-expression groups, a gene network represents pair-
wise relationships between genes, which contain information of modularities, subgraph
structures and other global properties such as centralities and closenesses. Second,
while SGLasso adopts an unsupervised strategy to cluster genes as predefined groups
for selection, Net-Cox identifies subnetwork signatures in a supervised manner, in which
the selected subnetworks are enriched by genes with large regression coefficients by the
design of the network constraint. In Table S3(g) in [35], we reported the results of
group Lasso and sparse-group Lasso in the five-fold cross-validation with the R package
“SGL” [121]. Compared with the CVPLs by the other methods in Table S3(a)-(f), the
CVPLs in Table S3(g) in [35] for group Lasso and sparse-group Lasso are consistently
lowest when 25 or 100 gene clusters are used as groups. Thus, we did not further
compare and analyze other results by the group Lasso models.
The experiments in this study clearly demonstrated that the network information is
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useful for improving the accuracy of survival prediction as well as increasing the consis-
tency in discovering signature genes across independent datasets. Since the signature
genes were discovered based on their relation in the networks, they enrich dense PPI
subnetworks, which are useful for pathway analysis. It is also interesting to note that
the PPI subnetworks of signature genes identified by Net-Cox on the TCGA dataset
is enriched by extracellular matrix proteins such as collagens, fibronectin, and decorin.
Previous gene expression studies had identified stromal gene signatures in ovarian tu-
mors to be associated with poor survival outcome [78]. Therefore, our observation that
the stromal subnetwork enriched by extracellular matrix proteins and stromal-related
proteins is consistent with the role of stromal gene signature in poor prognosis. Finally,
collagen matrix remodelling has been linked to platinum resistance, and ovarian cancer
cells grown on collagens are more resistant to platinum agents than their counterpart
grown on non-collagen substratum [122]. The tumor array validation indicates that
FBN1 can serve as a biomarker for predicting recurrence of platinum-sensitive ovarian
cancer.
Chapter 4
Network-based Isoform
Quantification with RNA-Seq
Data for Cancer Transcriptome
Analysis
4.1 Introduction
Application of next generation sequencing technologies to mRNA sequencing (RNA-Seq)
is a widely used approach in transcriptome study [123–125]. Compared with microarray
technologies, RNA-Seq provides information for expression analysis at transcript level
and avoids the limitations of cross-hybridization and restricted range of the measured
expression levels. Thus, RNA-Seq is particularly useful for quantification of isoform
transcript expressions and identification of novel isoforms. Accurate RNA-Seq-based
transcript quantification is a crucial step in other downstream transcriptome analy-
ses such as isoform function prediction in the pioneer work in [126], and differential
gene expression analysis [127] or transcript expression analysis [25]. Detecting biomark-
ers from transcript quantifications by RNA-Seq is also a frequent common practice in
biomedical research. However, transcript quantification is challenging since a variety
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of systematical sampling biases have been observed in RNA-Seq data as a result of li-
brary preparation protocols [21, 28, 128, 129]. Moreover, in the aligned RNA-Seq short
reads, most reads mapped to a gene are potentially originated by more than one tran-
script. The ambiguous mapping could result in hardly identifiable patterns of transcript
variants [28,29].
A useful prior knowledge that has been largely ignored in RNA-Seq transcriptome
quantification is the relation among the isoform transcripts by the interactions between
their protein products. The protein products of different isoforms coded by the same
gene may contain different domains interacting with the protein products of the tran-
scripts in other genes. Previous studies suggested that alternative splicing events tend to
insert or delete complete protein domains/functional motifs [130] to mediate key linkages
in protein interaction networks by removal of protein domain-domain interactions [131].
The work in [126, 132] also suggested unique patterns in isoform co-expressions. Thus,
the abundance of an isoform transcript in a gene can significantly impact the quantifica-
tion of the transcripts in other genes when their protein products interact with each other
to accomplish a common function as illustrated by a real subnetwork in Figure 4.1, which
is constructed based on domain-domain interaction databases [133,134] and Pfam [135].
Motivated by our observation that the protein products of highly co-expressed tran-
scripts are more likely to interact with each other by protein domain-domain binding
in four TCGA RNA-Seq datasets (see the section Results), we constructed two hu-
man transcript interaction networks of different sizes based on protein domain-domain
interactions to improve transcript quantification. Based on the constructed transcript
network, we propose a network-based transcript quantification model called Net-RSTQ
to explore domain-domain interaction information for estimating transcript abundance.
In the Net-RSTQ model, Dirichlet prior representing prior information in the tran-
script interaction network is introduced into the likelihood function of observing the
short read alignments. The new likelihood function of Net-RSTQ can be alternating-
optimized over each gene with expectation maximization (EM). It is important to note
that the Dirichlet prior from the neighboring isoforms play two possible roles. On one
hand, for the isoforms in the same gene but with different interacting partners, the dif-
ferent prior information will help differentiate their expressions to reflect their different
functional roles. On the other hand, for the isoforms in the same gene with the same
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interacting partners, the uniform prior assumes no difference in their functional roles
and thus, promotes a smoother expression patterns across the isoforms. In both cases,
the Dirichlet prior captures the functional variations/similarities across the isoforms in
each gene as prior information for estimation of their abundance.
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Figure 4.1: An isoform transcript network based on protein domain-domain
interactions. (A) The subnetwork shows the domain-domain interactions among tran-
scripts from four human genes, CD79B, CD79A, LCK and SYK. In the network, the
nodes represent isoform transcripts, which are further grouped and annotated by their
gene name; and the edges represent domain-domain interactions between two tran-
scripts. Each edge is also annotated by the interacting domains in the two transcripts.
(B) RefSeq transcript annotations of CD79A and CD79B are shown with Pfam domain
marked in color. The Pfam domains were detected with Pfam-Scan software. Note that
no interaction is included between transcripts NM 001039933 and NM 000626 of gene
CD79B without assuming self-interactions for modeling simplicity. For better visualiza-
tion, only the interactions coincide with PPI are shown in the figure.
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The chapter is organized as following. In the section Materials and Methods,
we describe the procedure to construct protein domain-domain interaction networks,
the mathematic description of the probabilistic model and the Net-RSTQ algorithm,
qRT-PCR experiment design, and RNA-Seq data preparation. In the section Results,
we first demonstrate the correlation between protein domain-domain interactions and
isoform transcript co-expressions across samples in four cancer RNA-Seq datasets from
The Cancer Genome Atlas (TCGA) to justify using domain-domain interactions as
prior knowledge. We then compared the predicted isoform proportions with qRT-PCR
experiments on 25 multi-isoform genes in three cell lines, H9 stem cell line, OVCAR8
ovarian cancer cell line and MCF7 breast cancer cell line. Net-RSTQ was also applied to
four cancer RNA-Seq datasets to quantify isoform expressions to classify patient samples
by the survival or relapse outcomes. In addition, simulations were also performed to
measure the statistical robustness of Net-RSTQ over randomized networks.
4.2 Materials and Methods
In this section, we first describe the construction of the transcript interaction network.
We then introduce the network-based transcript quantification model (Net-RSTQ) by
applying the protein domain-domain interaction information as prior knowledge based
on the base EM model mentioned in section 1.2.3. The notations used in the equations
are summarized in Table 4.1. At last, qRT-PCR experiment design and RNA-Seq data
preparation are explained.
Notation Description
N total # of genes
T set of transcripts; Tik is the k
th transcript of the ith gene; Ti denotes the transcripts of the i
th gene
lik length of transcript Tik
r set of reads; rij is the j
th read aligned to the ith gene; ri is the read set aligned to the i
th gene
pik the probability of a read generated by transcript Tik in the i
th gene
Pi the probability of a read generated by transcript Ti in the i
th gene, specifically, [pi1, ..., pi,|Ti|]
P concatenate of all Pi, specifically, [P1,P2, ...,PN ]
ρik relative abundance of the transcript Tik in the i
th gene
pi transcript expression; piik is the expression of the k
th transcript of the ith gene
φik average expressions (normalized) of transcript Tik’s neighbors in the transcript network
α parameters of Dirichlet distribution; αik = λφik + 1 is the parameter of the Dirichlet distribution of pik
qijk read sampling probability, qijk =
1
lik−lr+1 if read rij is aligned to transcript Tik, otherwise qijk = 0
S binary matrix for transcript interaction network
Table 4.1: Notations.
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4.2.1 Transcript network construction
Two binary transcript networks were constructed by measuring the protein domain-
domain interactions (DDI) between the domains in each pair of transcripts in four
steps. First, the translated transcript sequences of all human genes were obtained
from RefSeq [136]. Second, Pfam-Scan was used to search Pfam databases for the
matched Pfam domains on each transcript with 1e-5 e-value cutoff [135]. Note that
only high quality, manually curated Pfam-A entries in the database were used in the
search. Third, domain-domain interactions were obtained from several domain-domain
interaction databases, and if any domain-domain interaction exists between a pair of
transcripts, the two transcripts are connected in the transcript network. Specifically,
6634 interactions between 4346 Pfam domain families from two 3D structure-based DDI
datasets (iPfam [133] and 3did [134]) inferred from the protein structures in Protein
Data Bank (PDB) [137] were used in the experiments. Besides these highly confident
structure-based DDIs, transcript interactions constructed from 2989 predicted high-
confidence DDIs and 2537 predicted medium-confidence DDIs in DOMINE [138] were
also included if the transcript interaction agrees with protein-protein interactions (PPI)
in HPRD [139].
In the experiments, we focused on the transcripts from two cancer gene lists from
the literature for better reliability in annotations. The first smaller transcript network
consists of 11736 interactions constructed from the 3D structure-based DDIs and 421
interactions constructed from the predicted DDIs among the 898 transcripts in 397 genes
from the first gene list [140]. The second larger transcript network contains 711,516
interactions constructed from the 3D structure-based DDIs among 5599 transcripts in
2551 genes in a larger gene list [141]. Since inclusion of the predicted DDIs results in a
much higher density in the large network, the large network does not include predicted
DDIs to prevent too many potential false positive interactions. The characteristics of the
two transcript networks are summarized in Table 4.2. The density of the two networks
are 3.02% and 4.54% respectively, which are in similar scale with the PPI network.
Both networks show high clustering coefficients, suggesting modularity of subnetworks.
Note that self-interactions (interactions between transcript(s) in the same gene) are not
considered since Net-RSTQ only utilizes positive correlation between the expressions
of neighboring transcripts in different genes. For simplicity, Net-RSTQ assumes that
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self-interactions will not change the transcript quantification of an individual gene in
the model.
# of Gene # of Transcripts # of Interactions Density Diameter Avg. # of Neighbors Avg. Cluster Coefficients
Small Network 397 898 12157 3.02% 9 27.08 0.3578
Large Network 2551 5599 711516 4.54% 9 254.16 0.5255
Table 4.2: Network characteristics.
In Figure 4.1(A) a subnetwork of the transcripts in gene CD79A and CD79B with
their direct neighbors in the small transcript network is shown. The RefSeq transcript
annotations of CD79A and CD79B are shown in Figure 4.1(B). In CD79A transcript
NM 001783 contains an extra domain pfam07686 while transcript NM 021601 only con-
tains a shorter hit pfam02189. Note pfam02189 also has the same hit in NM 001783
with an e-value larger than 1e-5. In CD79B transcripts NM 001039933 and NM 000626
contain a domain pfam07686, which is removed in alternative splicing of NM 021602. In
the transcript subnetwork shown in Figure 4.1(A), the transcripts in CD79A or CD79B
have different interaction partners in the network. In the transcripts in CD79A, the
expression of NM 021601 will correlate with the transcripts in LCK and SYK, and
NM 001783 will correlate with two transcripts in CD79B. The isoform transcripts in
LCK and SYK show no different DDIs suggesting there is no functional variation by
protein bindings and more similar expression patterns are potentially expected as prior
knowledge.
4.2.2 Network-based transcript quantification model
In the Net-RSTQ model, the transcript interaction network S based on protein domain-
domain interactions is introduced to calculate a prior distribution for estimating P
jointly across all the genes and all the transcripts. The model assumes that the prior
distribution of Pi is a Dirichlet distribution specified by parameters αi and each αik is
proportional to the read count by average expression of the transcript Tik’s neighbors
in the transcript network S. The prior read count φik is defined as follows,
φik = lik(pi
′ S∗,(i,k)∑
(S∗,(i,k))
), (4.1)
where S∗,(i,k) is a binary vector represents the neighborhood of transcript Tik in tran-
script network S and
∑
(S∗,(i,k)) is the size of the neighborhood. The calculation of
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each φik is illustrated in Figure 4.2. The Dirichlet parameter αi is defined as a function
of φik as
αik = λφik + 1, (4.2)
where λ > 0 is a tuning parameter balancing the belief between the prior-read count
and the aligned-read count.
λαik=
C
0
C 1
1
1
1
0
? ′?ik
Tik:
Tg1a
Tg3c
:?
:?
×
…
…
g1a
=
g2b
g3c
g4dNeighbor(Tik) = {Tg1a,Tg2b,Tg3c,Tg4d}
Tg2b :?
Tg4d :?
g1a g2b
g4dg3c
?ik+1
αik
( ) lik
Figure 4.2: Transcript interaction neighborhood. In this toy example, transcript
Tik has four neighbor transcripts {Tg1a, Tg2b, Tg3c, Tg4d}, which are transcripts from g1,
g2, g3 and g4, respectively. The neighborhood expression φik of Tik is then calculated as
the average of its neighbor transcripts’ expressions and further normalized by transcript
length, represented as the vector product between pi and S∗,(ik) normalized by the
number of neighbors
∑
S∗,(ik) and the transcript length lik in the figure.
To obtain the optimal P jointly for all genes, we introduce a pseudo-likelihood model
to estimate P iteratively in each iteration. Assuming uniform Pr(ri), the pseudo-
likelihood function is defined as,
L(P ,α; r) =
N∏
i=1
L(Pi,αi; ri) =
N∏
i=1
Pr(Pi|αi)Pr(ri|Pi)
Pr(ri)
∝
N∏
i=1
Pr(Pi|αi)Pr(ri|Pi). (4.3)
Note that the pseudo-likelihood model relies on the independence assumption among the
likelihood functions of each individual gene when theα parameters of the Dirichlet priors
are pre-computed. Thus, the model simply takes the product of the likelihood function
from each gene. Each prior distribution Pr(Pi|αi) follows the Dirichlet distribution,
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Pr(Pi|αi) = C(αi)
|Ti|∏
k=1
pik
αik−1,where C(αi) =
Γ(
∑
k αik)∏
k Γ(αik)
. (4.4)
Integrating equations (1.7) and (4.4), the pseudo-likelihood function in equation
(4.3) can be rewritten with Dirichlet prior as
L(P ; r) =
N∏
i=1
C(αi) |Ti|∏
k=1
pik
αik−1
 |ri|∏
j=1
|Ti|∑
k=1
pikqijk

=
N∏
i=1
C(λφi + 1) |Ti|∏
k=1
pik
λφik
 |ri|∏
j=1
|Ti|∑
k=1
pikqijk
 . (4.5)
In the pseudo-likelihood function in equation (4.5), the only hyper-parameter λ
balances the proportion between the Dirichlet priors and the observed read counts of
each transcript. The larger the λ, the more belief put on the priors.
4.2.3 The Net-RSTQ algorithm
The Net-RSTQ algorithm optimizes equation (4.5) by dividing the optimization into
sub-optimization problems of sequentially estimating each Pi. Specifically, we fix all
Pc, c 6= i, and thus φi when estimating Pi with EM in each iteration and repeat
the process multiple rounds throughout all the genes. In each step, the neighborhood
expression φ is recomputed with new Pi for computing the quantification of the next
gene. For each sub-optimization problem, we estimate Pi with a fixed φ, the part of
the likelihood function in equation (4.5) involved with the current variables Pi is
L¯(Pi; ri) =
 ∏
g∈nb(i)
C(λφg + 1)
|Tg|∏
k=1
pgk
λφgk
C(λφi + 1) |Ti|∏
k=1
pik
λφik
|ri|∏
j=1
|Ti|∑
k=1
pikqijk
 , (4.6)
where nb(i) is the set of the genes containing transcripts that are neighbors of the
transcripts in gene i in the transcript network. Equation (4.6) consists of three terms
separated by the braces. The second and the third terms are the Dirichlet prior and the
likelihood of the observed counts in the data for gene i. The first term is the Dirichlet
priors of the neighbor transcripts of each Tik. These prior probabilities are involved since
φg are functions of the current variable Pi (equations (1.9), (4.1) and (4.2)). Equation
(4.6) cannot be easily solved with standard techniques. We adopt a heuristic approach
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to only take steps that will increase the whole pseudo-likelihood function in equation
(4.5). The Net-RSTQ algorithm is outlined below
Algorithm 1 Net-RSTQ
1: Initialization: random initialization or base EM (equation (1.7)) estimation of P (0)
2: for round t = 1, . . . do
3: P (t) = P (t−1)
4: for gene i = 1, . . . , N do
5: compute φi based on P
(t) with equations (1.9) and (4.1)
6: estimate Pi with EM algorithm (see next section)
7: if L¯(Pi) > L¯(P (t)i ) then
8: Pi
(t) = Pi
9: end if
10: end for
11: if max(abs(P (t) − P (t−1))) <1e-6 then
12: break
13: end if
14: end for
15: return P
In the algorithm, the outer for-loop between line 2-14 performs multiple passes of
updating P . The inner for-loop between line 4-10 scans through each gene to update
each Pi. Line 7 checks the the difference in the likelihood L¯ of gene i before and after the
estimated Pi is applied. The newly estimated Pi is kept in line 8 only if the likelihood
L¯ in equation (4.6) is higher. The convergence of P is checked at line 11. In each
sub-optimization problem, EM algorithm (described in the next section) is applied to
estimate Pi. After convergence, the transcripts expression pi can be learned by equation
(1.9) with the optimal P .
4.2.4 EM algorithm in Net-RSTQ
In line 6 of Algorithm 1, we maximize the likelihood function of the sub-optimization
problem in equation (4.6) to learn Pi given φi as
L(Pi; ri) =
C(λφi + 1) |Ti|∏
k=1
pik
λφik
 |ri|∏
j=1
|Ti|∑
k=1
pikqijk
 . (4.7)
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Note that equation (4.7) is the part of equation (4.6) without the Dirichlet priors of the
neighboring genes. In line 7 of Algorithm 1, the ignored Dirichlet priors are combined
with the likelihood in equation (4.7), when L¯(Pi) is computed, to evaluate the whole
likelihood in equation (4.6). The likelihood function in equation (4.7) is defined on
a categorical variable with Dirichlet prior, which can be solved with EM algorithm.
Following EM formulation in [20], the expectation aijk, a soft assignment of read j to
transcript k in gene i, is first estimated in the expectation step and Pi is then learned in
the maximization step. When φi is given, by taking log of equation (4.7) we can write
the EM steps to find Pi below.
E step:
Letting Match signify a matching between reads and transcripts, and Match(j) be
the transcript from which read j originates, we get:
log[L(Pi; ri,Match)] = logC(λφi + 1) +
|Ti|∑
k=1
λφik log(pik) +
|ri|∑
j=1
log(piMatch(j)qijMatch(j)), (4.8)
which leads to
Q(Pi|P (it)i ) = EMatch|ri,P (it)i
[log(L(Pi; ri))]
= logC(λφi + 1) +
|Ti|∑
k=1
λφik log(p
(it)
ik
) +
|ri|∑
j=1
|Ti|∑
k=1
(logp
(it)
ik
+ logqijk) ∗
p
(it)
ik
qijk∑|Ti|
k=1
p
(it)
ik
qijk
= logC(λφi + 1) +
|Ti|∑
k=1
λφik log(p
(it)
ik
) +
|ri|∑
j=1
|Ti|∑
k=1
aijk log(p
(it)
ik
) +
|ri|∑
j=1
|Ti|∑
k=1
aijk log(qijk) (4.9)
where it is the itth iteration in EM and
aijk =
p
(it)
ik qijk∑|Ti|
k=1 p
(it)
ik qijk
. (4.10)
M step:
Given that qijk and φi are known, the above reduces to maximizing
P
(it+1)
i = arg max
Pi
 |Ti|∑
k=1
λφiklog(pik) +
|ri|∑
j=1
|Ti|∑
k=1
aijklog(pik)
 . (4.11)
Using Lagrange multipliers and differentiating, equation (4.11) is maximized when
p
(it+1)
ik =
λφik +
∑|ri|
j=1 aijk∑|Ti|
k=1(λφik +
∑|ri|
j=1 aijk)
. (4.12)
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After EM algorithm converges, we update P with the newly estimated Pi only if the
update leads to increase of equation (4.6). It can be seen from equation (4.12) that the
role of λ is a parameter controlling the balance between the prior-read count and the
aligned-read count. To see that, recall φik is the prior-read count of transcript Tik by
the average expression of its neighbors (equation (4.1)) and
∑|ri|
j=1 aijk is the expected
aligned-read count of transcript Tik. λ directly balances the contributions from the two
terms. Therefore, a reasonable choice of λ should apply to RNA-Seq data with similar
level of noise or bias in general.
4.2.5 qRT-PCR experiment design
Three qRT-PCR experiments are designed to measure the isoform proportions of 25
multi-isoform genes in three cell lines, H9 stem cell line, OVCAR8 ovarian cancer cell
line and MCF7 breast cancer cell line. The cell lines were selected based on the available
of both RNA-Seq data and cell culture in our labs. The qRT-PCR experiments focused
on the gene with most different quantification results reported by Net-RSTQ and other
compared methods. Due to the limitations in time and cost of running qRT-PCR
experiments, only the 25 genes in the three cell lines were tested with all the results
reported in the experiments. Quantitation of the real-time PCR results was done on
the data from H9 human embryonic stem cells to obtain the absolute expressions for
comparing more than two transcripts and comparative Ct method was done on the data
from OVCAR8 ovarian cancer cells and MCF7 breast cancer cells to obtain the ratio
between a pair of transcripts.
H9 Stem cell line
Total RNA was extracted from human embryonic stem (ES) H9 cells by using TRIzol
(Invitrogen). To repeat the experiments of triplicate three times, 5µg RNA was used
to synthesize complementary DNA with ReverTra Ace (Toyobo) and oligo-dT (Takara)
according to the manufacturer’s instructions. Transcript levels of genes were determined
by using Premix Ex Taq (Takara) and analysed with a CFX-96 Real Time system (Bio-
Rad). The templates for different transcripts were generated with PCR by using the
template primers in S1 Table in [36]. After isolation and purification, the templates were
used to generate the standard curves with qRT-PCR by using the qRT-PCR primers for
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different transcripts. The generated standard curves have coefficient of determination
(R2) over 0.999. The qRT-PCR primers were then applied to determine the expression
levels of different transcripts in H9 ES cells by calculating with the standard curves.
The expressions were carried out in three independent replications and the standard
deviations were provided after the average.
Ovarian cancer cell line
1µg of total RNAs were isolated from untreated OVCAR8 cells using Trizol (Invitrogen).
RNA was reverse-transcribed using Superscript II reverse transcriptase (Invitrogen)
according to manufacture protocol. Real-time PCR was performed on CFX384 Real-
time system (Bio-Rad) with FastStart SYBR Green Master (Roche) with the primer
sets in S2 Table in [36]. PCR conditions are 10 min at 95◦C and 40 cycles of 95◦C for
45 sec and 60◦C for 45 sec. Quantitation of the real-time PCR results was done using
comparative Ct method. Two replicates of qRT-PCR were performed using total RNAs
isolated.
Breast cancer cell line
0.5µg of total RNAs purified from MCF7 cells was used for oligo d(T)20-primed reverse
transcription (Superscript III; Life Technologies). SYBR Green was used to detect and
quantitate PCR products in real-time reactions with the primer sets in S3 Table in [36].
PCR conditions for qRT-PCR analysis are 2 min 94◦C and 40 cycles of 94◦C for 30 sec,
60◦C for 20 sec and 72◦C for 30 sec. Quantitation of the real-time PCR results was done
using comparative Ct method. GAPDH mRNA was used as a normalization control for
quantitation. Three replicates of qRT-PCR were performed using total RNAs isolated.
4.2.6 RNA-Seq data preparation
Three cell line RNA-Seq datasets were used for evaluating the accuracy of transcript
quantification by comparison with qRT-PCR results. The first dataset is the H9 em-
bryonic stem cell line data from [142]. The raw RNA-Seq fastq file were downloaded
from SRA website (SRR1015682) under GEO accession GSE51607. The second dataset
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is an in-house dataset from the ovarian cancer cell line OVCAR8 prepared at Uni-
versity of Kansas Medical Center. The third dataset is the MCF7 breast cancer cell
line data from [143]. The raw RNA-Seq fastq file was downloaded from SRA website
(SRR925723) under GEO accession GSE48213. There are 23,397,325 single-end 34bp
reads in the stem cell line dataset, 19,892,473 paired-end 100bp reads in the OVCAR8,
and 21,855,632 paired-end 76bp reads in the MCF7 mapped to the human hg19 refer-
ence genome by TopHat2.0.9 [144] with up to 2 mismatches allowed. Exon coverages
and read counts of exon-exon junctions were generated by SAMtools [145] to be utilized
with Net-RSTQ and base EM (equation (1.7)). Cuﬄinks [23] directly infers transcript
expressions based on the alignment by TopHat with the min isoform fraction set to 0
for better sensitivity.
TCGA RNA-Seq datasets of Ovarian serous cystadenocarcinoma (OV), Breast in-
vasive carcinoma (BRCA), Lung adenocarcinoma (LUAD) and Lung squamous cell
carcinoma (LUSC) were analyzed for patient outcome prediction with transcript expres-
sions estimated by Net-RSTQ, base EM (equation (1.7)), RSEM [24] and Cuﬄinks [23].
Both the gene expression and transcript expression data reported by RSEM [24] in
TCGA (level 3 data) were utilized as two baselines for cancer outcome prediction. The
raw RNA-Seq fastq files (level 1 data) were downloaded from Cancer Genomics Hub
(CGHub) and processed by TopHat for use with Net-RSTQ, base EM and Cuﬄinks.
The patient samples in each dataset were classified into cases and controls based on the
survival and relapse outcomes as shown in Table 4.3. The command lines for preparing
the data with RSEM and Cuﬄinks are available in the S3 Text in [36].
Cancer Type Event # of Patients by years
Ovarian serous cystadenocarcinoma(OV) Survival 76(<3 ys) vs 62(>4 ys)
Relapse 79(<1.5 ys) vs 68(>2 ys)
Breast invasive carcinoma(BRCA) Survival 66(<5 ys) vs 57(>8 ys)
Relapse 42(<5 ys) vs 38(>8 ys)
Lung adenocarcinoma(LUAD) Survival 47(<2 ys) vs 56(>3 ys)
Lung squamous cell carcinoma(LUSC) Survival 67(<2 ys)vs 77 (>3 ys)
Table 4.3: Summary of patient samples in TCGA datasets. The samples are clas-
sified by cutoffs on survival and relapse time based on the available clinical information
in each dataset.
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4.3 Results
There are six major results in this section, 1) isoform co-expression analysis on TCGA
data to show the correlation with protein domain-domain interactions; 2) overlapping
the DDIs and KEGG pathways to understand the transcript networks; 3) simulations
for model validation and statistical analysis; 4) qRT-PCR experiments to measure the
performance of transcript quantification; 5) cancer outcome prediction on TCGA data
to measure the quality of transcript quantification as molecular markers; and 6) running
time of Net-RSTQ.
Net-RSTQ was compared with base EM (the base model in equation (1.7)), Cuf-
flinks [23] and RSEM (isoform expression or gene expression) [24]. The accuracy of
transcript quantification was directly measured on the simulated data with ground-truth
expressions and qRT-PCR data from the three cell lines. Cancer outcome prediction
on four TCGA cancer datasets evaluates the potential of using isoform expressions as
predictive biomarkers in clinical settings. Statistical assessment was also performed on
randomized transcript networks to evaluate the significance of the results.
4.3.1 Isoform co-expressions correlate with protein domain-domain in-
teractions
To investigate the correlation between protein domain-domain interactions and isofrom
transcript co-expressions, we calculated the number of transcript pairs that are both
nearby (being neighbors or having a distance up to 2) in the transcript network and
highly co-expressed in the TCGA samples. The transcript co-expressions were calculated
by Pearson’s correlation coefficients of each pair of transcripts across all the samples
in each dataset with the isoform transcript quantification by Cuﬄinks. The transcript
pairs were then sorted by the correlation coefficients from the largest to the smallest
and grouped into bins of size 1000. The number of transcript pairs that are nearby in
the transcript networks out of 1000 pairs are calculated within each bin and plotted
in Figure 4.3(A) and Figure 4.3(B) for the two cancer gene lists, respectively. In both
Figure 4.3(A) and Figure 4.3(B), the left column shows the plots of the number of pairs
that are neighbors in the transcript network, and the right column shows the plots of
the number of transcript pairs with a distance up to 2 in the transcript network, among
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the 1000 pairs in each bin. In all the plots, similar trends are observed in all the four
cancer datasets: there are more interacting isoform pairs in the bins with higher co-
expressions. For example, among the 1000 transcript pairs with the highest correlation
coefficients, there are 73 interactions in the transcript network in OV dataset and thus,
73 interactions (y-axis) for bin index 1 (x-axis) is plotted in the left column of Figure
4.3(A). In all the plots, there is a clear pattern that the numbers of matched nearby
transcripts in the transcript network among the 1000 pairs in the first few bins are
higher than the expected average of 30 in the small network of density 3.02%, 114 in
the small network of density 11.41% (with distance up to 2), 45 in the larger network
of density 4.54%, and 203 in the larger network of density 20.33% (with distance up
to 2). Moreover, the 2-step walk clearly promoted the number of overlaps with the
pairs of higher co-expressions in the small network. For example, the significant overlap
is extended from the first 25 bins to approximately the first 50 bins or more in the
four datasets. The observation suggests that higher co-expressions exist not only in the
direct neighbors in the transcript network but also the nearby nodes by a small distance.
By exploring the network structure with prior information through neighbors by many
steps in iterations, Net-RSTQ model is expected to propagate the expression values from
each transcript to its nearby nodes in the network to capture the co-expressions. Note
that considering the neighboring pairs with distance up to 2 in the larger network will
result in a graph of density 20.33%, which is likely to contain too many false relations
by the two-step walk. Thus, the plots of the larger network of distance-2 pairs are only
included for the completeness of the analysis.
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Figure 4.3: Correlation between transcript co-expression and protein domain-
domain interaction in TCGA datasets. The correlation coefficients between tran-
script expressions across all patient samples are first calculated in each dataset for each
pair of transcripts by Cuﬄinks. The correlation coefficients are then sorted from largest
to smallest and grouped into bins of size 1000 each. The x-axis is the index of the
bins with lower index indicating larger correlation coefficients. The y-axis is the num-
ber of the pairs among the 1000 pairs of transcripts in each bin coincide with protein
domain-domain interaction between the transcript pair. The red line is the smooth plot
by fitting local linear regression method with weighted linear least squares (LOWESS)
to the curves. p-value is reported by chi-square test. (A) Co-expressions are calculated
based on the small gene list. (B) Co-expressions are calculated based on the large gene
list. In both (A) and (B), the left column shows the plots based on the connected
transcript pairs in the transcript network and the right column shows the plots based
on the transcript pairs with distance up to 2 in the network.
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The canonical 2x2 chi-square test was also applied to compare the number of the
domain-domain interactions in the first 10,000 transcript pairs (first 10 bins) with the
number in the rest of the pairs. In all the four datasets in both Figure 4.3(A) and
Figure 4.3(B) with one exception in the LUSC dataset on the large network of distance-
2 relation, there is a significant difference that the highly co-expressed transcripts are
more likely to interact with each other in the transcript network, confirmed by the
significant p-values. As explained previously, the exception is likely due to the large
number of false-positive pairs in the dense network. The observation further support the
hypothesis that protein domain-domain interactions correlate transcript co-expressions
reported in previous studies [130,131].
To further understand the specificity of the domain-domain interactions in the highly
co-expressed transcripts, we calculated the number of domain-domain pairs that con-
struct the DDIs in the top 10,000 co-expressed transcript pairs. The statistics suggest
high diversity of the type of DDIs. For example, there are 547 interacting transcript
pairs among the 201 out of 898 transcripts in the top 10,000 co-expressed transcript
pairs in OV dataset for small network. The 547 interacting transcript pairs represent
770 different domain-domain interactions (There might be more than one DDIs between
a pair of transcripts). There are 739 interacting transcript pairs among the 538 out of
5599 transcripts in the top 10,000 co-expressed transcript pairs in OV dataset for large
network. The 739 interacting transcript pairs represent 1277 different domain-domain
interactions. The statistics suggest that the correlation between protein domain-domain
interactions and transcript co-expressions is not a bias due to a few highly spurious DDIs.
It is a general correlation in many different DDIs and co-expressed transcripts. Very
similar statistics were observed in all the datasets and both networks.
To further demonstrate the co-expression relations in the transcript network, two ex-
amples are shown in S1 Figure in [36]. In S1(A) Figure, WHSC1L1 contains two isoforms
connected with different interactions in the transcript network. Isoform NM 017778
interacts with 12 transcripts with average correlation coefficients 0.22 and the other
isoform NM 023034 interacts with 13 more transcripts with average correlation coef-
ficients 0.30 compared with the average correlation coefficient 0.188 against the other
unconnected isoforms across the samples in the OV dataset. In S1(B) Figure, gene
BRD4 contains two isoforms both of which are connected with the same 14 neighbors
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in the network. The average correlation coefficients between these two isoforms and
the 14 neighboring isoforms are both above 0.26 compared with the average correlation
coefficient less than 0.15 against the other unconnected isoforms across the samples on
the BRCA dataset. In both examples, we observed high degree of agreement between
co-expressions and DDIs.
4.3.2 Protein domain-domain interactions enrich KEGG pathways
To further understand the transcript networks, we overlapped the DDIs between genes
in the two networks with the 294 human KEGG pathways [146]. Among the 397 genes
in the small network, 10.97%(17284) of the pairs are co-members in at least one KEGG
pathway. The 10.97% KEGG co-member pairs covers 42.70%(2122) of the DDIs among
the genes while the other 89.03%(140352) non-co-member pairs covers 57.30%(2748) of
the DDIs. By these numbers, there is about 6-fold enrichment of DDIs in the KEGG
co-member genes in the small network. Among the 2551 genes in the large network,
the 5.15%(335372) KEGG co-member pairs covers 12.45%(40812) of the DDIs among
genes while the other 94.85%(6172229) non-co-member pairs covers 87.55%(287090) of
the DDIs. By these numbers, there is about 2.6-fold enrichment of DDIs in the KEGG
co-member genes in the large network. We also list the KEGG pathways that are highly
enriched with DDIs in the large network in S4 Table in [36]. Specifically, we consider
the subnetwork of genes that are members of one KEGG pathway and calculated the
density of DDIs in the subnetwork to compare to the overall density of 5.04% in the
whole network. Interestingly, most of the enriched pathways are signaling pathways and
disease pathways with very high DDI densities.
4.3.3 Net-RSTQ captures network prior in simulations
In the simulations, we applied flux-simulator [147] to generate paired-end short reads
simulating real RNA-Seq experiment in silico based on a ground truth transcript expres-
sion profile, using hg19 reference human genome and RefSeq annotations downloaded
from UCSC Genome Browser. To generate the ground-truth expression profiles, the
gene expressions were sampled from a poisson distribution and the proportions of the
isoforms in each gene were derived based on a neighbor average expression in the small
71
transcript network and an initial mixed power law expression profile with gaussian noise.
A sequential updating was used to compute the proportion of each isoform by adding
the neighbors’ average expressions to the initial expression. The update procedure
can be found in the S2 Text in [36]. At last, flux-simulator was applied to simulate
the short reads based on the ground truth transcript expression file. 15 million 76-bp
paired reads were generated by Flux Simulator and mapped to the reference genome
by TopHat [144] with up to two mismatches allowed. To account for the large dynamic
range of abundances, the expressions were normalized by log 2(expression+1).
The correlation coefficients between the transcript abundances estimated by Net-
RSTQ under various λ, base EM (equation (1.7)), Cuﬄinks and RSEM, and the ground
truth transcript abundances are reported in Figure 4.4. Furthermore, Net-RSTQ was
also tested with 100 randomized networks with permuted indexes of transcripts in the
transcript network. To assess the impact of the network prior, two cases are shown.
Figure 4.4(A) reports the correlation between the transcripts in which isoforms coded
by the same gene are connected with different neighbors (109 out of 898 transcripts in 29
genes). Figure 4.4(B) reports the results from all the genes with more than one isoform
(712 out of 898 transcripts in 211 genes). In both comparisons, the transcript expressions
estimated by Net-RSTQ achieve higher correlation with the ground truth compared
with base EM, Cuﬄinks and RSEM. Slightly higher improvement was observed in the
first case than in the second case since the network prior plays more significant role in
differentiating the isoform expressions by their different neighbors. When randomized
networks are used, Net-RSTQ leads to similar or worse results due to the wrong prior
information. Note that since the datasets were generated to partially conform to the
network prior, the isoform expressions are relatively “smooth” among the neighboring
isoforms. Net-RSTQ tends to generate smoother expressions than base EM, Cuﬄinks
and RSEM. When applying Net-RSTQ with small λs and randomized network priors,
slight improvement was also observed due to the smoothness assumption on the data.
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Figure 4.4: Correlation between estimated transcript expressions and ground
truth in simulation. In (A) and (B) x-axis are labeled by the compared methods and
different λ parameters of Net-RSTQ. The bar plots show the results of running Net-
RSTQ with 100 randomized networks. In (C) and (D), x-axis are are the percentage of
edges that are removed from the networks. The plots show the results of running Net-
RSTQ with the incomplete networks. (A) and (C) report the results of 109 transcripts
of the isoforms in the same gene with different domain-domain interactions. (B) and
(D) report the results of 712 isoforms in genes with multiple isoforms.
To evaluate the effect of missing edges in the transcript network due to the unde-
tected protein domain-domain interactions, we randomly removed certain percentages
of the edges in the transcript network and then run Net-RSTQ with λ = 0.1 on the
incomplete networks. The results are shown in Figure 4.4 (C) and (D) for the 109 tran-
scripts with different neighbors and the 712 transcripts in the gene with more than one
transcript, respectively. It is intriguing to observe that only when a large percentage of
the edges are removed, the performance of Net-RSTQ is affected. Intuitively, the obser-
vation can be explained by the fact that the Dirichlet prior parameter is proportional
to the average of the neighbors’ expressions. As long as some of the neighbors are still
connected to the target transcript in the network, the prior information is still useful.
The result suggests that Net-RSTQ is relatively robust to utilize transcript networks
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potentially constructed with a large percentage of undetected protein domain-domain
interactions.
4.3.4 Three qRT-PCR experiments confirmed overall improved tran-
script quantification
The isoform proportions estimated by Net-RSTQ, base EM, RSEM, and Cuﬄinks were
compared to the qRT-PCR results on the three cell lines. Parameter λ = 0.1 was fixed
in all the Net-RSTQ experiments. Among the genes that Net-RSTQ, base EM, RSEM,
and Cuﬄinks report most different quantification results, qRT-PCR experiments were
performed to test the genes with relatively higher coverage of RNA-Seq data, coding
two to three isoforms, and the feasibility of designing isoform-specific primers in the
qRT-PCR products (see S1, S2 and S3 Tables in [36]). Twenty-five genes in total
were tested in the three cell lines: seven in H9 stem cell line, five in OVCAR8 ovarian
cancer cell line, and thirteen in MCF7 breast cancer cell line. The scatter plots of the
relative abundance of the first transcript in each gene estimated by Net-RSTQ, base
EM, Cuﬄinks and RSEM were compared to the qRT-PCR results in Figure 4.5(A) and
(E). In the scatter plot, the estimated relative abundance by Net-RSTQ were closer
to qRT-PCR results measured by the accuracy of various thresholds and Root Mean
Square Errors. Net-RSTQ achieved the lowest Root Mean Square Error of 0.291, which
is more than 0.05 less than 0.3435, the second best achieved by RSEM. In the 20%
confidence region, Net-RSTQ puts 59.3% of the pairs in the region compared with 37%,
29.6%, and 51.9% by base EM, Cuﬄink, and RSEM, respectively. RSEM performed
well by putting 37.0% of the pairs within 10% confidence regions but performed poorly
in about half of the pairs with more than 25% error.
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(A) All three cell lines (B) H9 stem cell line
(C) OVCAR8 ovarian cancer cell line (D) MCF7 breast cancer cell line
Accuracy
Cut-off Net-RSTQ base EM Cuﬄink RSEM
0.1 29.6% 18.5% 18.5% 37.0%
0.15 44.4% 33.3% 22.2% 40.7%
0.2 59.3% 37.0% 29.6% 51.9%
0.25 74.4% 44.4% 33.3% 51.9%
Root Mean Square Error 0.2915 0.3701 0.4111 0.3435
(E) Accuracy and correlation
Figure 5. Validation by comparison with qRT-PCR results. (A) The scatter plots compare the
reported relative proportion of each pair of the isoforms of each gene between the computational methods
(Net-RSTQ, EM and Cuﬄinks) and qRT-PCR experiments. The proportions of the two compared isoforms in a
pair are normalized to adding to 1. The x-axis and y-axis are the relative proportion of one of the two isoform
(the other is 1 minus the proportion) reported by qRT-PCR and the computational methods, respectively. The
scatter points aligning closer to the diagonal line indicate better estimations by a computational method
matching to the qRT-PCR results. The unshaded gradient around the diagonal line shows the regions with
scatter differences less than 0.1, 0.15, 0.2 and 0.25, within which the estimations are more similar to the
qRT-PCR results. (B)-(D) The scatter plots on each individual dataset. (E) The table shows the percentage of
predictions by each method within the unshaded regions and the overall correlation coefficients between the
predictions by each method and the qRT-PCR results.
Figure 4.5: Validation by comparison with qRT-PCR results. (A) The scatter
plots compare the reported relative proportion of each pair of the isoforms of each gene
between the computational methods (Net-RSTQ, base EM, Cuﬄinks, and RSEM) and
qRT-PCR experiments. The proportions of the two compared isoforms in a pair are
normalized to adding to 1. The x-axis and y-axis are the relative proportion of one of
the two isoform (the other is 1 minus the proportion) reported by qRT-PCR and the
computational methods, respectively. The scatter points aligning closer to the diagonal
line indicate better estimations by a computational method matching to the qRT-PCR
results. The unshaded gradient around the diagonal line shows the regions with scatter
differences less than 0.1, 0.15, 0.2 and 0.25, within which the estimations are more
similar to the qRT-PCR results. (B)-(D) The scatter plots on each individual dataset.
(E) The table shows the percentage of predictions by each method within the unshaded
regions and the overall Root Mean Square Error of the predictions by each method
compared to the qRT-PCR results.
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The relative abundance of the seven genes in H9 stem cell line is shown in Fig-
ure 4.5(B), S2(A) Figure and S5 Table in [36]. In all seven genes tested, the relative
abundance estimated by Net-RSTQ is closer to the qRT-PCR results compare to that
by base EM and Cuﬄinks. RSEM performed similarly well on four genes and worse
on the other three genes, CBLC, TCF3 and NPM1. The same comparison on the five
selected genes in OVCAR8 ovarian cancer cell line is shown in Figure 4.5(C), S2(B)
Figure and S6 Table in [36]. Cuﬄinks reports very low expressions in the first tran-
script in four genes, three of which do not agree with the highly expressed transcript
in the qRT-PCR results. While base EM performed better for two genes (NSD1 and
HNRNPA2B1), Net-RSTQ performed better on the other three genes (HRAS, TSC2,
and WHSC1L1). Net-RSTQ correctly predicted the overall enrichment of isoforms of
HNRNPA2B1 and NSD1 (NM 031243 > NM 002137 in HNRNPA2B1 and NM 022455
> NM 172349 in NSD1). It is possible that the expressions of NM 002137 transcript in
gene HNRNPA2B1 and NM 172349 in gene NSD1 were slightly over-smoothed by net-
work information in Net-RSTQ with the fixed λ parameter. RSEM performed slightly
better on WHSC1L1 and NSD1 but much worse in the other three genes. The same
comparison on the thirteen genes in MCF7 breast cancer cell line is shown in Figure
4.5(D), S2(C) Figure and S7 Table in [36]. Cuﬄinks performed poorly on 8 genes with
more than 25% error while RSEM, base EM and Net-RSTQ performed poorly on 5,
4 and 3 genes, respectively. Overall, Net-RSTQ performed better than base EM and
Cuﬄinks and slightly better than RSEM. In summary, Net-RSTQ improved the overall
isoform quantification significantly in the H9 stem cell data and predicted more consis-
tent cases in OVCAR8 and MCF7 cancer cell lines data. Note that there could be more
uncertainties in primer designs due to somatic DNA variations and cell differentiation
and proliferation in cancer cell lines, potentially a larger variation in the qRT-PCR
experiments on the cancer cell lines is expected than H9 stem cell line.
4.3.5 Net-RSTQ improved overall cancer outcome predictions
To provide an additional evaluation of the quality of transcript quantification, we de-
signed six cancer outcome prediction tasks by the assumption that better transcript
quantification always leads to better isoform markers for cancer outcome prediction.
Net-RSTQ was compared with base EM, RSEM [24], and Cuﬄinks [23] by classification
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with the quantification of isoform transcripts in two cancer gene lists (397 and 2551
genes) on four cancer datasets. Each dataset is divided into four folds with two folds for
training, one fold for validation (parameter tuning), and one fold for test in a four-fold
cross-validation. Support Vector Machine (SVM) with RBF kernel [49] were chosen as
the classifier. We repeated the four-fold cross-validation 100 times by each method in
each dataset.
The average area under the curve (AUC) of receiver operating characteristic of the
100 repeats are reported in Table 4.4 when the small gene list was used and Table 4.5
when the large gene list was used. The transcript expressions estimated by Net-RSTQ
consistently achieved better average classification results than those by the base EM.
To evaluate the statistical significance of the differences between the AUCs generated
by Net-RSTQ and the base EM in the 100 repeats, we also report the p-values by a
binomial test on the number of wins/loses in all the experiments between Net-RSTQ
and the base EM in Table 4.4 and Table 4.5. When the small gene list was tested, three
cases were significant with low p-values less than 0.001 and two cases were significant
with p-values just below 0.02 while in the BRCA (survival) data, the p-value is only
moderately significant even though the average by Net-RSTQ is higher. Overall, Net-
RSTQ outperformed the base EM significantly. When the larger gene list was tested,
the improvements are not as significant. The improvement was only significant in one
dataset, BRCA (survival), and slightly significant in two datasets, OV (relapse) and
LUSC (survival). In the other three datasets, the improvements are not significant.
Net-RSTQ also outperformed Cuﬄinks and RSEM (transcript or gene) in five cases
except the experiment on BRCA (relapse) dataset in Table 4.4. In Table 4.5, the
improvements are less obvious. Moreover, the isoform expression features are not more
informative than gene expression features. Overall, the classification performance with
the small gene list in Table 4.4 is generally better than or similar to the large gene list
in Table 4.5 possibly suggesting less relevance to survival and relapse in the large gene
list.
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Dataset OV(Survival) OV(Relapse) BRCA(Survival) BRCA(Relapse) LUAD(Survival) LUSC(Survival)
Net-RSTQ(Isoform) 0.5973 0.6070 0.6826 0.5902 0.6353 0.5666
base EM(Isoform) 0.5696 0.5886 0.6727 0.5419 0.5789 0.5496
RSEM(Isoform) 0.5865 0.5501 0.6510 0.6156 0.6132 0.5362
Cuﬄinks(Isoform) 0.5630 0.5770 0.6762 0.5933 0.5554 0.5563
RSEM(Gene) 0.5911 0.5804 0.6513 0.5581 0.6151 0.5585
p-value(Net-RSTQ vs base EM) 0.0011 0.0198 0.1356 2.248e-5 1.948e-8 0.0167
Table 4.4: Classification performance of estimated transcript expressions and
gene expression on the small cancer gene list. The mean AUC scores of classifying
patients by estimated transcript (gene) expression in four-fold cross-validation for each
dataset are reported. The best AUCs across the five models using isoforms as features
are bold.
Dataset OV(Survival) OV(Relapse) BRCA(Survival) BRCA(Relapse) LUAD(Survival) LUSC(Survival)
Net-RSTQ(Isoform) 0.5989 0.5852 0.6793 0.5920 0.6038 0.5662
base EM(Isoform) 0.5901 0.5720 0.6509 0.5710 0.5971 0.5555
RSEM(Isoform) 0.5842 0.5694 0.6629 0.5935 0.5867 0.5432
Cuﬄinks(Isoform) 0.5623 0.5819 0.6825 0.5800 0.5834 0.5591
RSEM(Gene) 0.6041 0.5766 0.6746 0.5980 0.6266 0.5535
p-value(Net-RSTQ vs base EM) 0.3798 0.0967 0.0018 0.3822 0.6178 0.1356
Table 4.5: Classification performance of estimated transcript expressions and
gene expression on the large cancer gene list. The mean AUC scores of classifying
patients by estimated transcript (gene) expression in four-fold cross-validation for each
dataset are reported. The best AUCs across the five models are bold.
The parameter λ was tuned by the AUC on the validation set and the optimal
λ was used to train the Net-RSTQ model to be tested on the test set. The process
is repeated for each fold in 100 repeats. To show the effect of varying the λ on the
classification performance in Net-RSTQ, we plotted the average AUC on the validation
set across the 100 repeats on the BRCA (survival) dataset with small gene list in S3(A)
Figure in [36]. The optimal λ was 0.1 in this experiment. The local gradient around the
optimal λ suggesting that the transcript network is playing an important role in inferring
better transcript quantification from the RNA-Seq data. In S3(B) Figure in [36], the
convergence of Net-RSTQ is also illustrated by each update through all the genes in each
iteration. After less than 10 overall iterations across 397 genes, Net-RSTQ converged
well to a local optimum. Similar convergence patterns were observed in all other TCGA
samples.
To understand the role of the transcript network in the transcript expression esti-
mation, we used 100 randomized networks to learn the transcript proportion in each
experiment with λ fixed to be 0.1. In each randomization, the edges were shuﬄed
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among all the transcripts in the small gene list. For transcript expressions learned by
each randomized network, we conducted the same four-fold cross validation to compute
the average AUCs among 100 repeats. The boxplot of the AUCs learned with the 100
randomized networks is shown in Figure 4.6. Compared with the classification results
from the true transcript network, the result with randomized networks is always worse.
Another important observation is that, the median value of the AUCs across the 100
randomized networks is lower or close to the result by the base EM, which suggests
that the randomized networks play no role in improving classification and even lead to
worse result. Overall, the results provide a clear evidence that the transcript network is
informative for the transcript expression estimation, and supplies more discriminative
features for cancer outcome prediction.
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Figure 4.6: Statistical analysis with randomized networks. Comparison of the
classification results by the randomized networks and the true network. The λ parameter
was fixed to be 0.1 in all the experiments. The blue star and the red star represent the
results with the real network and without network (base EM), respectively. The boxplot
shows the results with the randomized networks.
4.3.6 Running time
To measure the scalability of Net-RSTQ, we tested the Net-RSTQ algorithm on the data
of the MCF7 breast cancer cell line with three different networks, the small network
(898 transcripts), the large network (5599 transcripts) and an artificial huge network
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(10000 transcripts). Figure 4.7 plots the CPU seconds of running Net-RSTQ on the
three networks under different λs. On the small network, the running time is at most
about 100 seconds while on the large network and the huge network, the running time
is in the scale of 1-e3∼1-e4 and 1-e5∼1-e6, respectively. When λ = 0.1, the CPU time
for the small network is 32.4 seconds; for the large network is 2755 seconds; and for
the artificial large network is 27806 seconds. The results suggest that Net-RSTQ might
scale up to about 10000 transcripts, and thus the performance is sufficient for studies
focusing on any pathway with up to several thousand genes in the pathway.
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Figure 4.7: Running time. The plots show the CPU time (Intel Xeon E5-1620
with 3.70GHZ) for running the Net-RSTQ algorithm one three networks, the small
transcript network, the large transcript network, and an artificial huge network of 10000
transcripts.
4.4 Discussion
In the study, we explored the possibility of improving short-read alignment based tran-
script quantification with relevant prior knowledge, protein domain-domain interactions.
The observation of the correlation between isoform co-expressions and protein domain-
domain interactions suggests that the approach is a well-grounded exploration. Differ-
ent from previously methods [22], Net-RSTQ is a network-based approach that directly
incorporates protein domain-domain interaction information for transcript proportion
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estimation. The experiments suggested a great potential of exploring protein domain-
domain interactions to overcome the limitations of short-read alignments and improve
transcript quantification for better sample classification.
The Dirichlet prior from the neighboring isoforms play two different roles: differ-
entiating isoform expressions to reflect different functional roles or smoothing isoform
expressions to reflect similar functional roles, depending on whether the isoforms of a
gene share the same or different interacting partners. This principle in modeling is
based on the hypothesis that isoforms playing different functional roles (e.g. containing
different protein domains) are more likely to behavior differently than isoforms with
the same or similar functional roles (e.g. containing the same protein domains). When
the isoforms of a gene interact with different partners, their expressions correlates with
their partners’ expressions. And, when the isoforms of a gene interact with the same
partners, there is no benefit on differentiating their proportions to drive the function-
ality. A limitation is that when the functional difference among the isoforms are not
captured by domain content, the smoothing role might under-estimate the difference in
their proportions. Thus, our future goal is to bring in other type of functional infor-
mation to distinguish their functional roles in cancer such as preferential adoption of
post-transcriptional regulations.
Currently, Net-RSTQ does not directly model multi-hits reads in multiple loci. In the
TCGA experiments, around 5-10% of the aligned reads in four datasets have multiple
alignments reported by TopHat and only one of the best alignments is considered.
To check the effect of the multiple-alignment reads in transcript quantification, we
allow up to 20 best alignments by TopHat and normalized the read assignment qijk
by the number of loci that the reads aligned to. The correlation coefficients between
the estimated gene expressions before and after the normalization are above 0.98 in all
the datasets. A potential rigorous solution is to add iteratively reassignment of the
reads to the potential origins based on updated abundance of the involved isoforms.
The modification will significantly decrease the computational efficiency and make it
impractical on large RNA-Seq datasets.
There is also another alternative of integrating the network information directly as a
regularization term on the joint likelihood function of all the genes. We also explored this
model in the S1 Text in [36]. In the preliminary experiments, we observed very similar
81
outputs between the alternative model and the Net-RSTQ model shown in S8 Table
in [36]. However, since the alternative model directly works with one large optimization
problem across all the genes, the convergence is much slower as shown in S4 Figure
in [36] and the optimization package used in the experiments ran into numerical issues.
Thus, we believe the Net-RSTQ model is more scalable and robust in comparison.
Currently, Net-RSTQ can scale on transcript network with up to around 5000 tran-
scripts, which is sufficient for more focused analysis of several thousand genes. The
running time of Net-RSTQ on such large transcript network is below 2 hours on each
TCGA sample, compared with 5-8 hours needed for aligning the short reads. To fur-
ther scale up Net-RSTQ, we will investigate other faster strategies of utilizing short
read information, such as Sailfish [148] which directly estimates isoform expressions by
counting k-mer occurrences in reads rather than reads from the alignments. This will
be our future direction.
Chapter 5
Detecting mRNA 3’-UTR
shortening in mTORC1 activated
MEFs
5.1 Introduction
In eukaryotes, a large portion of mRNAs contains multiple polyadenylation signals
(PASs) in their 3’-untranslated region (3’-UTR). Alternating the usage of PAS, namely
alternative cleavage and polyadenylation (ApA), produces mRNA isoforms with the
same coding capacity but with various lengths of 3’-UTR [7,149–151]. As 3’-UTR pro-
vides a binding platform for microRNAs and RNA-binding proteins, it serves as an im-
portant determinant for mRNA fate such as translation and stability [149,150,152,153].
Therefore, ApA provides an additional layer of complexity in regulating gene expres-
sion at the posttranscriptional level. Powerful high-profiling technologies focusing on
3’-UTRs of mRNAs provided high-resolution snap shots of alternatively polyadenylated
mRNA isoforms in various tissues and cells across many species [4,153–157]. An impor-
tant insight that emerged from these studies is that 3’-UTR length undergoes dynamic
changes under pathogenic conditions such as cancer and in diverse biological processes
such as cell proliferation, differentiation and development [23, 149, 153, 154, 158, 159].
Although the information on alternative polyadenylation sites in transcriptomes across
82
83
different species and tissues is rapidly accumulating, it is not clear what cellular mech-
anism(s) controls the switches between proximal and distal polyadenylation sites and
how this process is regulated.
The mammalian target of rapamycin (mTOR) pathway is crucial for regulating cell
proliferation/growth and its dysregulation causes many human diseases [160]. mTOR
exists as two distinctive multi-protein complexes, mTORC1 and mTORC2. Raptor and
Rictor are specific components of mTORC1 and mTORC2, respectively, and they are
essential for cellular function of each mTOR complex [160,161]. mTORC1 is negatively
regulated by tuberous sclerosis complexes (TSC1 and TSC2) and is an evolutionarily
conserved kinase that phosphorylates the ribosomal protein S6 kinases and the eu-
karyotic initiation factor 4E-binding proteins for efficient translation [160,161]. Recent
studies identified cis-acting elements in mRNAs such as 5’-terminal oligopyrimidine tract
(TOP) or 5’-pyrimidine-rich translational element (PRTE) that render the association
of a transcript with polysomes. mRNAs containing these elements in their 5’-UTRs
encode proteins for cellular pathways including translation, cell invasion and metasta-
sis, suggesting their relevance in cancer pathogenesis [162, 163]. mTOR also plays an
important role for activating transcriptional networks and regulates multiple cellular
pathways for lipid and nucleotide metabolism [164,165]. Recently, mTOR was shown to
play a role in the regulation of proteasome activity by upregulating a transcription fac-
tor Nrf-1 (ref. [166]). Although these studies were mainly focusing on the role of mTOR
in the synthesis of proteins, lipids and nucleic acids through transcriptional networks,
whether mTOR is involved in other cellular processes by modulating gene expression at
posttranscriptional level is relatively unclear.
In this study, we used isogenic non-cancerous mouse embryonic fibroblast (MEF) cell
lines to understand changes of molecular features on dysregulated activation of mTOR.
We employed RNA sequencing (RNA-seq) and two-dimensional liquid chromatography
tandem mass spectrometry (2D LC-MS/MS) approaches to investigate the changes at
high resolution and found an unexpected link between mTOR and ubiquitin-mediated
proteolysis pathway through 3’-UTR shortening. These findings expand our under-
standing of mTOR to regulation of RNA processing and protein degradation pathways.
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5.2 Results
5.2.1 3’-UTR shortening of mRNAs is caused by mTOR activation
and is a down stream target of mTORC1
Figure 5.1: mTOR activation leads to genome-wide 3’-UTR shortening. (a)
RNA-seq reads from WT and TSC1−/− are aligned to mouse genome mm10 RefSeq.
Representative examples of transcripts with 3’-UTR shortening are presented. Anno-
tated gene structures are at the bottom of the alignment. The yellow boxes highlight
the aligned reads in 3’-UTRs. (b) Scatter plot of RNA-seq data. Red dots represent
individual transcripts in the analysis. Horizontal blue-dashed lines represent the cutoff
values for twofold changes in differential gene expression. Vertical green-dashed lines
represent the cutoff values for log10 (p-value) of 3’-UTR shortening (1.3 corresponds to
p-value=0.05) in TSC1−/− and WT, which was determined by χ2-test. (c) A schematic
presenting primer sets for RT-qPCR and the RSI determination. Pairs of primers were
used to detect a total (short+long) or a long-specific transcript. The RSI was calculated
to determine the 3-UTR shortening in a target cell line by RT-qPCR. (d) Validation of
RNA-seq data. Error bars represent s.e. from three repeats of experiments. Student’s
t-tests are done for statistical significance. ∗p-value <0.0025.
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To explore mTOR function in gene expression at a single nucleotide resolution, we
performed RNA-seq experiments (Supplementary Table 1 in [34]) using Tsc1 knockout
(TSC1−/−) and wild-type (WT) MEF cells [167]. Knockout of Tsc1, a negative regulator
of mTOR, leads to uncontrolled mTOR hyperactivation compared with WT [167,168].
One of the striking features in our data set was that many transcripts in TSC1−/−
showed an abrupt signal drop only for a segment of the 3’-most exon of an annotated
gene compared with WT (Fig.1a and Supplementary Fig.1a in [34]). For example, the
read signal for Dicer1 in TSC1−/− dropped after the termination codon in the 3’-most
exon, although the signal from upstream exons increased (Fig.1a). In some cases, up-
stream exons showed either similar (for example, Mecp2 and Tomm20) or decreased (for
example, Anxa7 and Timp2) signal, although we observed the same pattern of signal
drop in the 3’-most exon from TSC1−/− (Fig.1a and Supplementary Fig.1a in [34]). Fur-
ther sequence analysis revealed that canonical or non-canonical PAS(s) exists around the
regions showing the signal drop. This indicates that the synthesis of these transcripts
terminated early in the 3’-most exon using the proximal PASs for polyadenylation, sug-
gesting a predominant production of mRNA isoforms with a shorter 3’-UTR in the
mTOR-activated transcriptome (Fig.1a and Supplementary Fig.1a in [34], yellow box,
and Supplementary Data 1 in [34]). For some transcripts such as Tomm20 and Nampt,
3’-UTR-shortened transcripts were already present in WT where the mTOR activity is
low but not entirely absent (Fig.1a and Supplementary Fig.1a in [34]). These 3’-UTR-
shortened transcripts increased significantly in TSC1−/− (Fig.1a and Supplementary
Fig.1a in [34]), indicating that individual transcripts differ in the regulation of their
3’-UTR length in response to cellular mTOR activity. As the signals from upstream ex-
ons reflecting the amount of transcripts varied among the 3’-UTR-shortened transcripts,
we examined whether 3’-UTR shortening in the mTOR-activated transcriptome corre-
lates to differential gene expression. To this end, we enriched 5,160 transcripts in our
data set that are eligible for combined analysis of 3’-UTR shortening and differential
expression (see Methods for details). Next, each transcript was plotted by fold changes
in the differential gene expression (y axis in Fig.1b) and the significance of 3’-UTR
shortening (x axis in Fig.1b). This approach identified 846 3’-UTR-shortened tran-
scripts (about 16.4%) out of 5,160 transcripts in TSC1−/− (Fig.1b). Although 26.3%
(223/846) of the 3’-UTR-shortened transcripts either increased (147/846) or decreased
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(76/846) their expression level, a significant proportion (73.7%) of them in the mTOR-
activated transcriptome remained unchanged (Fig.1b), indicating no strong correlation
between the differential gene expression and the 3’-UTR shortening in the mTOR-
activated transcriptome. Of note, only a small percentage (1.3%) of transcripts showed
3’-UTR shortening in WT over TSC1−/− MEFs. To confirm the RNA-seq data, we
developed a method to determine 3’-UTR shortening or lengthening by calculating rel-
ative shortening index (RSI) (see Methods for details; Fig.1c). Twelve genes, covering
a wide range of p-values, were randomly selected from the 3’-UTR shortening data set;
all showed the RSI >0 in TSC1−/− (Fig.1d and see also Supplementary Fig.1d,e in [34]
for alternative presentations of the data using different experimental and calculation
methods), validating our RNA-seq data analysis. Together, these data strongly suggest
that mTOR activation in cells leads to a preferred usage of proximal PAS in the 3’-most
exon of mRNAs and results in transcriptome-wide 3’-UTR shortening.
To determine whether 3’-UTR shortening due to ApA is a previously uncharac-
terized cellular target downstream of mTOR pathway, our collaborator established a
stable mTOR knockdown cell line TSC1−/− MEFs (TSC1−/− mTOR kd; Supplemen-
tary Fig.2a in [34]). The tested transcripts showed the RSI <0 in TSC1−/− mTOR
kd MEFs as compared with a control knockdown cell line, indicating the enrichment
of 3’-UTR-lengthened transcripts in mTOR-deficient cells (Fig.2a and Supplementary
Fig.2b in [34]), thus supporting the idea that mTOR functions in 3’-UTR length regula-
tion. Consistently, the same results were observed in a human embryonic kidney stable
cell line and a bladder cancer cell line with the same treatment [169,170]. These results
suggest that the function of mTOR in 3’-UTR shortening is a general phenomenon and
evolutionarily conserved between human and mouse (Supplementary Fig.2c-e in [34]).
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Figure 5.2: 3’-UTR shortening is a downstream target of mTORC1. (a) mTOR
knockdown (kd) in TSC1−/− recovers the 3-UTR length. The RSI was measured using
total RNAs isolated from TSC1−/− MEFs with mTOR kd. ∗p-value<0.015. (b) Activa-
tion of mTOR in terminally differentiated skeletal muscle leads to 3’-UTR shortening.
Total RNAs from skeletal muscles in WT or skeletal muscle-specific knockout of Tsc1
(SM TSC1−/−) mice were used for the RSI measurement. The brain was used as an
additional tissue control. Western blotting on tissue extracts from two randomly cho-
sen mice was done. p-S6 denotes phosphorylated S6, a downstream target of activated
mTOR kinase. ∗p-value<0.016. (c) mTORC1 but not mTORC2 is crucial for 3’-UTR
shortening. mTORC1 or mTORC2 was specifically deactivated by targeting Raptor or
Rictor, respectively, using short hairpin RNAs in TSC1−/− MEFs. The RSI was mea-
sured using RT-qPCR. ∗p-value<0.05. (d) A selective inhibitor of mTOR, Torin1, alters
3’-UTR length in mRNAs. TSC1−/− MEFs were treated with Torin1 at various doses
(10, 50 and 250nM, presented as incremental triangles) and time courses (3, 6 and 12h).
Changes in the 3’-UTR length were determined by measuring the RSI. ∗The conditions
that accumulate the long 3’-UTR-containing transcripts with statistical significance.
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Proliferative cells are known to carry short 3’-UTRs in their transcriptome and
terminally differentiated tissues are known to produce transcripts with long 3’-UTRs
[153,154,157]. We asked whether mTOR activation could be an underlying reason that
explains these observations. The experiments done by our collaborator on a mouse
model with skeletal muscle provide evidence that the mTOR activation is sufficient
to drive 3’-UTR shortening in terminally differentiated skeletal muscles (Fig.2b and
Supplementary Fig.2m in [34]).
To address which mTOR complex regulates 3’-UTR shortening, our collaborator es-
tablished stable cell lines using short hairpin RNA that specifically knocks down Raptor
(a component of mTORC1) or Rictor (a component of mTORC2) in TSC1−/− MEFs
(Supplementary Fig.2g in [34]). The knockdown of Raptor but not Rictor resulted in
the RSI <0 when compared with control knockdown cells, suggesting that mTORC1
plays an important role in 3’-UTR shortening (Fig.2c and Supplementary Fig.2h in [34]).
mTOR is a key therapeutic target for many human disease treatments [160] and several
versions of selective mTOR inhibitors have been developed including Torin1 (ref. [171]).
The experiments done by our collaborator shows that the cellular ApA pattern changes
drastically on the pharmacological inhibition of mTOR (Fig.2d and Supplementary
Fig.2i,j,n in [34]). Furthermore, our collaborator proved that the 3’-UTR lengthening
after Torin1 treatment is not caused by the inhibition of cell proliferation but rather
from the inactivation of mTOR (Supplementary Fig.2r,s in [34]). Taken together, we
conclude that the mTOR pathway is an upstream regulator for ApA process and deter-
mines the 3’-UTR length in the transcriptome independent of cell proliferation status.
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5.2.2 3’-UTR shortening activates ubiquitin-mediated proteolysis
Figure 5.3: 3’-UTR shortening due to mTOR activation targets specific cellu-
lar pathways including ubiquitin-mediated proteolysis. (a) Analysis of mTOR-
activated proteome. The KEGG pathway enrichment analysis was performed using the
catalogue of identified proteins from 2D LC-MS/MS. The left panel shows the enriched
pathways in log10(p-value). The right box shows the distribution of individual proteins
in each KEGG pathway index shown in the left panel. Proteins showing more than 1.2
fold changes in TSC1−/− compared with WT MEFs are plotted. Ubiquitin-mediated
proteolysis pathway is marked with a light green box. (b) Analysis of enriched KEGG
pathways by 3’-UTR shortening in TSC1−/− MEFs. The mTOR-activated transcrip-
tome is described in Figure 1. The KEGG pathways enriched in TSC1−/− MEFs by
3’-UTR shortening are shown in log10(p-value). Fold changes of individual proteins
in each pathway index are plotted in the right box. Ubiquitin-mediated proteolysis
pathway is marked with a light green box. (c) The RSI was measured for the tran-
scripts enriched in ubiquitin-mediated proteolysis pathway in TSC1−/− MEFs. The
lengthening of 3’-UTR in TSC1−/− MEFs treated with Torin1 at 50nM for 24h was
shown by the RSI. ∗p-value<1.5×10−6, ∗∗p-value<6.3×10−6. (d) Western blot analysis
of E2 and E3 enzymes showing the 3’-UTR shortening in the RNA-seq experiments.
Cells were treated with Torin1 for 24h at 50nM for 3’-UTR lengthening. pS6 denotes
phosphorylated S6.
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Activation of mTOR increases global protein synthesis by controlling multiple down-
stream events such as ribosome biogenesis and cap-dependent translation initiation and
elongation [160,161]. Especially, mTOR promotes the translation of a subset of mRNAs
carrying 5’-UTR sequences such as 5’TOP, 5’TOP-like motif and 5’PRTE [162, 163].
Similar to 5’-UTR, 3’-UTR in mRNA also plays an important role in the regulation
of gene expression. In particular, 3’-UTR shortening in a transcript has been shown
to increase protein production [150, 153, 154, 172]. Therefore, we asked whether the
mTOR-activated 3’-UTR shortening contributes to mTOR-mediated upregulation of
protein synthesis and influences mTOR-related biology. To this end, our collaborator
first conducted quantitative proteomic studies using tandem mass tag (TMT)-labelled
total cell lysates prepared from WT and TSC1−/− MEFs, to quantitatively profile the
changes in the cellular proteome due to mTOR activation. They identified a total of
2,754 proteins that were found in either cell line by two or more unique peptides via
2D LC-MS/MS (Supplementary Data 2 in [34]). I did the KEGG (Kyoto Encyclopedia
of Genes and Genomes) enrichment analysis on the catalogue of proteins with >20%
increase (1,014 proteins) in abundance (TSC1−/− compared with WT) and found that
multiple cellular pathways are activated in TSC1−/− (Fig.3a). We also performed the
KEGG pathway analysis using the catalogue of 846 3’-UTR-shortened transcripts (Sup-
plementary Data 1 in [34]) and the differentially expressed transcripts in TSC1−/− MEFs
(Supplementary Fig.3a and Supplementary Data 3 in [34]). By comparing the enriched
pathways from these three data sets, we found that multiple pathways in the mTOR-
activated proteome such as spliceosome (mmu03040) and RNA degradation (mmu03018)
are upregulated by both 3’-UTR shortening and differential gene expression, whereas
other enriched pathways such as DNA replication (mmu03030) and pyrimidine/purine
metabolism (mmu00240/mmu00230) are attributable solely to the differential gene ex-
pression (Fig.3a and Supplementary Fig.3a,b in [34]).
Intriguingly, among those enriched pathways in the quantitative proteome analy-
sis, ribosome- (mmu03010) and ubiquitin-mediated proteolysis pathways (mmu04120)
did not appear in the differential gene expression data set (Fig.3a and Supplementary
Fig.3b,c in [34]). This indicates that these two pathways are most likely to be ac-
tivated by other mTOR-mediated regulatory mechanisms rather than transcriptional
regulation. It is known that the ribosome pathway is activated by mTOR through the
91
translational regulation of mTOR-responsive 5’-UTR cis-elements such as 5’TOP and
5’PRTE in the mRNAs [162,163,173]. On the other hand, mTOR-responsive 5’-UTR se-
quence elements do not exist in most transcripts from the ubiquitin-mediated proteolysis
pathway, supporting the idea that 3’-UTR shortening could be an explanation for the
activation of ubiquitin-mediated proteolysis pathway in the mTOR-activated proteome
(the light green box in Fig.3a,b and Supplementary Fig.3d in [34]). All transcripts from
the ubiquitin-mediated proteolysis pathway containing short 3’-UTR encode the com-
ponents of E2 ubiquitin-conjugating enzymes and E3 ubiquitin ligases such as Anapc1,
Rbx1, Trip12, Ube2i and Tceb1. Consistent with our findings in this study, these tran-
scripts carry an mTOR-dependent short 3’-UTR in TSC1−/− MEFs as determined by
the RSI in the presence or the absence of Torin1 treatment (Fig.3c). As shown by
western blotting (Fig.3d), the expression of Ube2i, Ube2b and Rbx1 proteins matched
the progression of 3’-UTR shortening in these transcripts, supporting our conclusions
from quantitative proteomics studies and 3’-UTR-shortening analysis. Together, these
results suggest that 3’-UTR shortening by mTOR activation plays an important role in
altering gene expression. These results also identify the ubiquitin-mediated proteolysis
pathway as an additional cellular target of mTOR. Thus, mTOR-driven 3’-UTR short-
ening might explain part of cellular phenotypic changes in TSC1−/− over WT MEFs.
5.3 Method
5.3.1 RNA-Seq and alignments
To evaluate transcriptome features under mTOR hyperactivation at nucleotide-wise
resolution, we performed RNA-seq analysis of poly(A+) RNAs isolated from WT and
TSC1−/− MEFs. In total, 63,742,790 paired-end reads for WT and 74,251,891 paired-
end reads for TSC1−/− MEFs were produced from Hi-Seq pipeline with length of 50bp of
each end. The short reads were aligned to the mm10 reference genome by TopHat [174],
with up to two mismatches allowed. The unmapped reads were first trimmed to remove
poly-A/T tails (repeats of [A/N]s or [T/N]s) from read ends/starts and then aligned to
the reference genome. It is worth noting that we only retained the reads with at least
30bp in both ends after trimming. Finally, 87.1% of short reads from WT and 87.5% of
sequence reads from TSC1−/− MEFs were mapped to the reference genome by TopHat
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for ApA analysis in the study.
5.3.2 ApA analysis
To detect the potential alternative PAS of a transcript between WT and TSC1−/−
MEFs, we evaluated candidate PAS motifs (AATAAA, ATTAAA, AGTAAA, CATAAA,
TATAAA, GATAAA, ACTAAA, AATACA, AATATA, AAGAAA, AATAGA, AAT-
GAA, TTTAAA, AAAATA, TATATA, AGATAA, ATTACA, AGAATA) [31, 175] in
the 3’-UTR of the transcript by contrasting the short-read coverage up/downstream of
the site across WT and TSC1−/− samples with χ2-test. Specifically, we first scanned
the 3’-UTR of a transcript (by mm10 annotation) to identify PAS motifs as candidates
of alternative PAS. For each candidate PAS, we calculated the mean coverage upstream
of the site (N and M) and downstream of the site (n and m) with (N, n) denoting the
coverage in WT and (M, m) denoting the coverage in TSC1−/−. In the calculation, the
upstream region starts at the beginning of the last coding exon adjacent to the 3’-UTR
of the transcript and ends at the beginning of the PAS motif site. Next, a canonical
2×2 χ2-test was applied to report a p-value for each candidate site. The candidate PAS
with the most significant p-value ≤0.05 was considered for further analysis. It is note-
worthy that the χ2-test will report shortening events in both WT (when N/n>M/m)
and TSC1−/− (when N/n<M/m). Out of the 5,160 transcripts, 846 (16.4%) show a
p-value ≤0.05 in TSC1−/− MEFs and 69 (1.3%) a show p-value ≤0.05 in WT MEFs.
5.3.3 Scatter plot for differential expression and ApA analysis
To select candidate transcripts with sufficient signal for reliable differential expression
analysis and 3’-UTR-shortening identification, we first analysed the short-read align-
ments of the RNA-seq data against mouse mm10 reference genome using Cuﬄink [23].
In the alignments, 14,378 and 14,175 transcripts are considered ‘expressed’ in WT and
TSC1−/− cell lines, respectively, with a FPKM (fragments per kilobase of transcript per
million mapped reads) cutoff=0.17. The union of the two sets gives 15,340 transcripts
that are expressed in at least one of the cell lines. We further filtered out the transcripts
with positional short-read coverage ≤25 in the entire 3’-UTR in both cell lines. In ad-
dition, transcripts with 3’-UTR overlapping exons in the strand in opposite direction
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were removed to avoid mingled short-read signals that might lead to inaccurate 3’-UTR-
shortening identification. Finally, to allow precise PAS analysis, only transcripts with
at least two occurrences of the 18 PAS motifs in the 3’-UTR are retained in the study.
The entire pruning procedure left 5,160 transcripts for further analysis.
5.3.4 Measurement of RSI
A numerical presentation of 3’-UTR shortening was developed by calculating the RSI of
a given transcript. A relative expression of total or longer 3’-UTR-containing transcripts
was measured by normalizing to total amount of RNAs used in RT-qPCR analysis. The
following equation was used to determine the RSI.
LI=[normalized expression of longer 3’-UTR-containing transcript]/[normalized ex-
pression of total (long+short) transcript]
RSI=log2(LI/[LI in reference cell line]); thus, RSI=0 for a reference cell line.
If RSI >0 in a target cell line, then there is a 3’-UTR shortening. If RSI <0 in a
target cell line, then there is a 3’-UTR lengthening. The RSI contains the information
about the changes in the proportion of a longer 3’-UTR-containing transcript in a given
cellular context compared with a reference cell. For example, a value of 1 in the RSI of
a transcript indicates that the proportion of the longer 3’-UTR-containing transcript of
the total (long+short) transcript decreases by 50% compared with that of the reference
cell line, indicating an enrichment of 3’-UTR-shortened transcript (that is, 3’-UTR
shortening).
5.4 Discussion
In this study, we used genetically well-defined MEFs to investigate the molecular signa-
tures of mTOR-activated transcriptome and discovered widespread 3’-UTR shortening
due to dysregulated mTOR activation. Although a precise mechanism(s) of how mTOR
activation leads to the 3’-UTR shortening in selected transcripts is unknown, we found
that almost all known 3’-end processing factors alter their expression on changes in cel-
lular mTOR activity in TSC1−/− compared with WT MEFs, suggesting that mTOR-
mediated 3’-UTR shortening occurs by multiple factors (Supplementary Data 3 in [34]).
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Analysis on pathways enriched in 3’-UTR-shortened transcripts and quantitative pro-
teomics on mTOR activation identified ubiquitin-mediated proteolysis as an additional
target pathway of mTOR. Considering the well-documented function of mTOR in the
activation of cellular anabolic metabolism for rapid cell proliferation [176], the newly dis-
covered function of mTOR in ubiquitin-mediated proteolysis through 3’-UTR shortening
is surprising. A recent study suggests a role of mTOR in the activation of proteasome
through the modulation of a transcriptional network [166]. This study argued that the
promotion of protein degradation pathway on mTOR activation is required for a con-
tinuous supply of amino acids to cellular systems, to maintain the steady-state protein
synthesis. Our data set also indicates a marginal increase in the proteasome activity
through a transcriptional upregulation of several proteasomal subunits (Supplementary
Fig.4d in [34]) and an increase in the polyubiquitination of proteins on mTOR activation
(Supplementary Fig.4i in [34]). Moreover, our data demonstrate that mTOR-promoted
3’-UTR shortening leads to the overexpression of selected E2 and E3 components in ubiq-
uitin ligase complexes (Figs 3b,d), which is known to increase polyubiquitination of their
substrates [177–183]. Therefore, it is possible that the enrichment of polyubiquitination
in cellular proteins on mTOR activation could come from selective polyubiquitination of
those E2 and E3 substrates. Together, our study proposes the molecular mechanism of
how mTOR pathway selects proteins to degrade through 3’-UTR shortening of a subset
of mRNAs. The E2 and E3 enzymes upregulated by mTOR-driven 3’-UTR shortening
mostly target cell cycle regulators, tumour suppressors and pro-apoptotic proteins for
ubiquitin-proteasome system [178,184]. For instance, Rbx1, Trip12 or Anapc1/5 are all
components of E3 ligase complexes that selectively polyubiquitinate Arf and Cyclins,
and Birc6 E3 ligase targets Caspase 3/7 for degradation [178, 184, 185]. For rapidly
proliferating cells, a timely removal of cell cycle regulators such as Arf and Cyclins is a
key step for rapid progression of the cell cycle [178]. Therefore, our findings are particu-
larly important, because unlike a previous argument it explains how upregulated mTOR
and consequent proteasome activation recycles proteins that are only needed to foster
a cellular environment favourable to rapid cell proliferation. Thus, we suggest that this
selective proteolysis not only provides a surplus of amino acids to cellular systems but
also makes cells proliferate rapidly by efficient modulation of the cellular levels of cell
cycle regulators.
Chapter 6
Conclusion and Discussion
This thesis has presented several network-based learning methods and a pipeline for uti-
lize high-dimensional microarray gene expression and RNA-Sequencing genomic data
that integrate biological prior knowledge for cancer transcriptome analysis. We ap-
proached this problem with three consecutive directions. (1) Accurate quantification of
the molecular features in the genomic data. (2) Develop reliable methods to identify
the reproducible cancer relevant biomarkers from all the candidate genomic features.
(3) Develop robust predictive models for patient samples classification. In this chapter,
we summarized the works present in the thesis based on the three directions mentioned
above and then a discussion of possible extensions of the works.
6.1 Conclusion
Accurate quantification of molecular features is the crucial step in other downstream
transciptome analysis such as isoform function prediction, biomarker identification, and
patient samples classification. In the thesis, (1) we described a network-based method
Net-RSTQ integrate protein domain-domain interaction network with short read align-
ments for transcript abundance estimation in Chapter 4. Compared to the existing
methods, Net-RSTQ is proven a useful tool for isoform-based analysis in functional
genomes and systems biology validated by qRT-PCR experiments, simulation and clas-
sification of TCGA patient samples. All the experiments suggested a great potential of
exploring protein domain-domain interactions to overcome the limitations of short-read
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alignments. (2) We developed a pipeline for the study in Chapter 5 to quantify the
different polyadenylation sites in the 3’-UTR region for the same gene with RNA-Seq
data. We then identified ApA events between TSC1−/− and WT based on the quantified
polyadenylation with χ2-test. The experiments support the accuracy of the identified
ApA events.
Discovered biomarkers can possibly provide better prognosis and diagnosis than the
current available clinical measures for risk assessment of cancer patients. Building re-
liable computational methods to identify reproducible cancer relevant biomarkers from
high-throughput genomic data is a challenge problem. In the thesis, (1) we present
network propagation models Signed-NP for feature selection in high-dimensional mi-
croarray gene expression for detecting differentially expressed genes in Chapter 2. (2)
We introduce a network-based Cox regression model Net-Cox to identify relevant fea-
tures for survival analysis in cancer genomics in Chapter 3. Both models presented in
these two chapters introduce a graph Laplacian matrix as a smoothness requirement
on the gene features linked in the gene relation network. The gene relation network is
constructed by co-expression analysis or prior knowledge of gene functional relations.
Compared to the existing models, introducing a gene relation network in the model
capture more global relation among all the genes, such as centralities, closenesses, mod-
ularities, and subgraph structures. The experiments in Chapter 2 and 3 show that
the network-based methods identified highly consistent signature genes across several
datasets for the same study purpose. Moreover, the identified signature genes contain
more discriminative power for cancer prediction and survival prediction compared with
the marker genes identified by the other methods. One of the marker genes, FBN1,
which was detected as a signature gene of high confidence by Net-Cox with network
information, was validated as a biomarker for predicting early recurrence in platinum-
sensitive ovarian cancer patients in laboratory.
Developing a predictive model based on the identified molecular features or the
whole feature space for cancer patient survival prediction or classification is critical
for cancer treatment and etiology. The classification model, Signed-NPBi, which is
described in Chapter 2, is a semi-supervised learning algorithm on bipartite graphs was
introduced to explore sample-feature bi-clusters for feature selection and cancer outcome
classification. Large scale experiments on several microarray gene expression datasets
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and CNV datasets validated that Signed-NPBi performed better classification of gene
expression and CNV data than the existing methods. The survival prediction model,
Net-Cox, which is described in Chapter 3 also consistently improved the accuracy of
survival prediction over the Cox models regularized by L2-norm or L1-norm.
In summary, all models proposed in this thesis showed promising results in both
simulations and experiments on real high-throughput genomic data, and the findings
are useful for the cancer studies.
6.2 Future Work
In this section, we will discuss several future directions extending the work presented in
this thesis.
6.2.1 Transfer learning across cancers
We introduce a transfer learning framework to discover common genomic features shared
across different cancer types and cancer specific features to extend the work proposed
in Chapter 2.
Suppose we have δ datasets (studies/cancer types) measured from the same p ge-
nomic features, each dataset i contains ni samples. We can learn the common genomic
features across the datasets and datasets specific features from
L(fc,fi) =
δ∑
i=1
[
α(fc + fi)
TLi(fc + fi) + (1− α)‖fc + fi − yi‖22 + γ1‖fi‖1
]
+γ2‖fc‖1, (6.1)
where fc is the common feature vector and fi is the feature vector specific in dataset
i. Alternating optimize fc and fc can solve the problem in equation 6.1. When fc is
fixed, we can learn one fi at a time, which is equivalent to solve a lasso penalized linear
regression problem. The same for updating fc.
We can also extend the framework in equation 6.1 on a bipartite graph as a semi-
supervised learning model to identify common cancer genomic features, cancer specific
features, and classify the samples in each study simultaneously. Suppose we have δ
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studies and i is the index of the studies. S(i) = D
− 1
2
v(i) ∗W ∗D
− 1
2
u(i) .
L(fv(c) ,fv(i) ,fu(i)) =
δ∑
i=1
{‖fv(c) + fv(i)‖22 + ‖fu(i)‖22 − 2(fv(c) + fv(i))TS(i)fu(i)
+α‖fv(c) + fv(i) − yv(i)‖22 + α‖fu(i) − yu(i)‖22
+λ1‖fv(i)‖1}+ λ2‖fv(c)‖1 (6.2)
where fv(c) is the common feature vector, fv(i) is the feature vector specific in dataset
i, and fu(i) is the label vector for the samples in dataset i.
6.2.2 Improving transcript quantification by integrating RNA-Seq and
NanoString/qRT-PCR data
We introduce an integrative model to learn the transcript expression by integrating
RNA-Seq data and NanoString/qRT-PCR to provide the accurate transcript quantifi-
cation with the same purpose of the algorithm, Net-RSTQ described in Chapter 4.
Instead of providing all the individual isoform expression in the gene, NanoString or
qRT-PCR only need to provide the expression of the isoform groups in the gene as a
reference. For example, suppose there are five transcripts in gene A, we only need to
design the primers for NanoString(or qRT-PCR) to separate the five transcripts into at
least two groups, the groups can be overlapped with each other. The objective function
can be formulated to learn the probability pik of a read generated by transcript Tik in
the ith gene as follow,
Pi = arg max
Pi
 |ri|∑
j=1
log(
|Ti|∑
k=1
pikqijk)− λ‖Gi|ri| − αEi‖2
 , (6.3)
where Pi is the probability of a read generated by transcript Ti in the i
th gene, specif-
ically, Pi = [pi1, ..., pi,|Ti|]. Ei is the expression of the isoform groups in the i
th gene
estimated from NanoString(or qRT-PCR). α is a parameter make the expressions esti-
mated by RNA-Seq and NanoString(or qRT-PCR) are comparable. Gi is the relative
abundance of the isoform groups in the ith gene which is a function of pik.
Equation 6.3 consists of two terms. The first term is the log-likelihood of the observed
read counts in the data for gene i, and the second term encourages consistency between
the expressions reported by RNA-Seq and NanoString (or qRT-PCR).
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6.2.3 Identify 3’-UTR shortening by integrating RNA-Seq and PAS-
Seq data
The pipeline to identify the ApA events presented in Chapter 5 is solely based on the
candidate PAS motifs since the exact polyadenylation sites in the 3’-UTR region are not
available. It may not accurately estimate the cleavage position from the candidate PAS
to identify the ApA events. A recently developed deep sequencing-based method called
Poly(A) Site Sequencing (PAS-Seq) for quantitatively profiling RNA polyadenylation
at the transcriptome level [186] is available. PAS-Seq not only accurately and com-
prehensively identifies polyadenylation sites in mRNAs and noncoding RNAs, but also
provides quantitative information on the relative abundance of polyadenylated RNAs.
By integrating PAS-Seq data with RNA-Seq data, we can improve the pipeline presented
in Chapter 5 with an integrative model to identify 3’-UTR shortening events.
The integrative model can be formulated to learn the probability pik of a read
generated by the polyadenylated RNA Cik in the i
th gene as follow,
Pi = arg max
Pi
 |ri|∑
j=1
log(
|Ci|∑
k=1
pikqijk)− λ‖Pi|ri|
Li
− αEi‖2
 , (6.4)
where Pi is the probability of a read generated by the polyadenylated RNA Ci in the i
th
gene, specifically, Pi = [pi1, ..., pi,|Ci|]. Li is a vector contains the length of the 3’-UTRs
for polyadenylated RNAs in the ith gene. Ei is the expression of the polyadenylated
RNAs in the ith gene estimated from PAS-Seq. α is a parameter to make the expression
estimated by RNA-Seq and PAS-Seq comparable.
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